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SOMATIC GENOME EDITING IN SICKLE CELL
DISEASE: REWRITING A MORE JUST FUTURE*
VENCE L. BONHAM** & LISA E. SMILAN***
Genome-editing technologies promise novel therapies for
hematologic disorders. Sickle cell disease (“SCD”), the most
common inherited blood disorder, has been identified as one
condition where somatic genome editing may provide a cure to
alleviate the burden and suffering of the disease. SCD has been
slated as one of the first targets for Phase I clinical trials. Given
the legacy of discrimination and health inequities for individuals
living with the disease and individuals living with sickle cell trait
(“SCT”), carriers of one sickle cell gene, policymakers and
scientists developing genome-editing research and clinical
programs must consider the history of SCD. This Article surveys
the social and legal context of SCD and current somatic genomeediting research. It maintains that development and access to
curative genetic therapies should be based on the principle of
fairness. Equitable application of human genome editing must
serve as the core legal, ethical, and social compass that guides the
implementation of somatic genome-editing research and clinical
treatment. Proactive steps must be taken to ensure that SCD
globally is not left behind in the development of genome-editing
technologies.
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INTRODUCTION
Approximately 1,000 children in Africa are born with SCD every
day and more than half will die before they reach five.1
In 1910, Dr. James Herrick described a blood cell irregularity in
his article, “Peculiar Elongated and Sickle-Shaped Red Blood
Corpuscles in a Case of Severe Anemia,” in the Archives of Internal
Medicine: this “peculiar” phenomenon later came to be known as
SCD.2 The identification of this disease within the Western medical
community was an important milestone in the science of human
genetics. Today, SCD is used to describe several inherited blood
disorders, including sickle cell anemia, HbSC, and HbSβthalassaemia.3 Throughout the history of SCD—the most common
single-gene disease—treatment of this community has been
intertwined with race and inequities in health care.
While the pharmacological revolution of the last twenty-five
years failed to benefit the SCD community, during the last five years
promising new drugs and genetic curative treatments have emerged.4
While acknowledging the promise and potential of novel genetic
therapies to end suffering of those with SCD, this Article considers
the historical context of the disease and how that history affects
current ethical, legal, and social implications of the research.
The National Academies of Sciences, Engineering, and Medicine
2017 Report on Human Genome Editing identifies fairness as an
important principle, requiring
that like cases be treated alike, and that risks and benefits be
equitably distributed (distributive justice). Responsibilities that
flow from adherence to this principle include (1) equitable
distribution of the burdens and benefits of research and (2)

1. AM. SOC’Y OF HEMATOLOGY, STATE OF SICKLE CELL DISEASE: 2016 REPORT
22 (2016), http://www.scdcoalition.org/pdfs/ASH%20State%20of%20Sickle%20Cell%
20Disease%202016%20Report.pdf [https://perma.cc/KQ7E-372W].
2. James B. Herrick, Peculiar Elongated and Sickle-Shaped Red Blood Corpuscles in
a Case of Severe Anemia, 5 ARCHIVES INTERNAL MED. 517 (1910), reprinted in 74 YALE
J. BIOLOGY & MED. 179, 179 & cmt. a (2001).
3. Catherine Booth, Baba Inusa & Stephen K. Obaro, Infection in Sickle Cell
Disease: A Review, 14 INT’L J. INFECTIOUS DISEASES e2, e2–e3 (2010).
4. See, e.g., Chris Morris, The Story Behind the New Sickle Cell Drug That Was 25
Years in the Making, CNBC (Aug. 7, 2017, 9:58 AM), https://www.cnbc.com/2017/08/07/
new-sickle-cell-anemia-drug-endari-by-emmanus-is-fda-approved.html
[https://perma.cc/
N9QY-R2JD].
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broad and equitable access to the benefits of resulting clinical
applications of human genome editing.5
Fairness, which includes equitable access, must be at the forefront in
developing both policies and clinical trials. The commitment of every
stakeholder engaged in the research, development, production, and
provision of the new technology will be required to address this
challenging goal—essentially, that grand scientific advances in
biotechnology must translate into health care for underserved
patients. The pharmaceuticals industry, government regulators and
policymakers, legislators, bioethicists, health-care professionals, and
insurers cannot operate in isolation; each must invite the voices of
patients and their advocates to join in collaborative dialogue and
policymaking.
This Article describes the discrimination that SCD patients have
faced in the past and proposes a fairness-based framework to guide
future treatment and research to ensure equitable access to somatic
gene editing in the SCD community.6 Part I of the Article discusses
current advances in gene editing and its potential to cure disease. Part
II provides an overview of SCD and how somatic genome editing may
someday cure individuals with the disease. Part III contemplates the
legacy of discrimination endured by the SCD community, which may
inform the community’s concerns regarding inequitable access to new
treatments. Part IV considers the importance of engaging in
5. NAT’L ACADS. OF SCIS., ENG’G, & MED., HUMAN GENOME EDITING: SCIENCE,
ETHICS, AND GOVERNANCE 12 (2017); see also NAT’L COMM’N FOR THE PROT. OF
HUMAN SUBJECTS OF BIOMEDICAL & BEHAVIORAL RESEARCH, THE BELMONT
REPORT: ETHICAL PRINCIPLES AND GUIDELINES FOR THE PROTECTION OF HUMAN
SUBJECTS OF RESEARCH 10, https://videocast.nih.gov/pdf/ohrp_belmont_report.pdf
[https://perma.cc/NND4-RLRY] (“[W]henever research supported by public funds leads
to the development of therapeutic devices and procedures, justice demands both that
these not provide advantages only to those who can afford them and that such research
should not unduly involve persons from groups unlikely to be among the beneficiaries of
subsequent applications of the research.”).
6. Somatic Genome Editing is
the alteration of cells that cannot contribute to gamete formation and thus cannot
be passed on from the individual to offspring. In contrast, germline genome
editing, . . . refers to genome editing that occurs in a germ cell or embryo and
results in changes that are theoretically present in all cells of the embryo and that
could also potentially be passed from the modified individual to offspring. In
theory, modification of gamete-producing cells at any point in development could
permit this. Because human germline genome editing has potential effects on both
the treated individual and subsequent generations of persons, it entails ethical
considerations beyond those of somatic genome modification.
Kelly E. Ormond et al., Human Germline Genome Editing, 101 AM. J. HUM. GENETICS
167, 169 (2017).
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conversations with the SCD community about its thoughts, beliefs,
hopes, and fears relating to curative genetic therapies and how such
engagement may forestall perpetual health inequities. Part V provides
an overview of current legal protections relating to genetic
information and its limitations concerning diagnosed genetic diseases.
Part VI considers the idea of equity and gene editing, spotlighting
new approaches to ensure inclusion and affordability for the SCD
community.
I. GENOME EDITING AND THE POTENTIAL OF CURING DISEASE
Genome editing is a “group of [techniques] that give scientists
the ability to change an organism’s” genome by removal or change in
genetic material, specifically deoxyribonucleic acid (“DNA”) or
ribonucleic acid (“RNA”).7 In humans, a vector to edit a gene can
either be delivered outside the body (ex vivo treatment) or the
vectors can be injected into the body (in vivo treatment).8 These
techniques “allow genetic material to be added, removed, or altered
at particular locations in the genome.”9
In 2012, Jennifer Doudna, Emmanuelle Charpentier, and their
colleagues published a groundbreaking report on how Clustered
Regularly Interspaced Short Palindromic Repeats (“CRISPR”), when
combined with an enzyme called CRISPR protein 9 (“Cas9”), could
be programmed to edit the DNA of virtually any living organism.10
Enthusiasm about CRISPR—a naturally occurring, ancient defense
mechanism deployed by bacteria to destroy invading viruses—stems
from its precision and low cost relative to comparable techniques.11
Feng Zhang and his colleagues were the first to use genome-editing
techniques in eukaryotic cells including human cells.12 In 2015, Science
named CRISPR as the “Breakthrough of the Year,” describing it as a
“molecular marvel” and recognizing the exponential growth in the

7. What Are Genome Editing and CRISPR-Cas9?, NIH: GENETICS HOME
REFERENCE, https://ghr.nlm.nih.gov/primer/genomicresearch/genomeediting [https://perma.cc/
JHJ6-E7VV] (last updated Apr. 30, 2019).
8. How Does Gene Therapy Work?, NIH: GENETICS HOME REFERENCE,
https://ghr.nlm.nih.gov/primer/therapy/procedures
[https://perma.cc/63KF-66VV]
(last
updated Apr. 30, 2019).
9. What Are Genome Editing and CRISPR-Cas9?, supra note 7.
10. Martin Jinek et al., A Programmable Dual-RNA-Guided DNA Endonuclease in
Adaptive Bacterial Immunity, 337 SCIENCE 816, 816 (2012).
11. Id.; see also Mark Shwartz, Target, Delete, Repair, STAN. MED., Winter 2018, at 20,
27 (explaining that “CRISPR has made gene editing cheap, easy and accessible”).
12. Le Cong et al., Multipex Genome Engineering Using CRISPR/Cas Systems, 339
SCIENCE 819, 820 (2013).

97 N.C. L. REV. 1093 (2019)

1098

NORTH CAROLINA LAW REVIEW

[Vol. 97

scientific community’s understanding of the tool and how it could be
applied within various clinical, environmental, and ecological
contexts.13
The medical utility of CRISPR gene editing has continued to
develop at a rapid pace. In 2016, doctors in China began using
CRISPR-Cas9 to edit immune cells from lung cancer patients to
inactivate the protein PD-1, which therefore made immunotherapy
more effective.14 In mid-2017, researchers successfully used a
variation of the CRISPR tool to correct the mutation underlying
Duchenne muscular dystrophy (“DMD”), both in patient-derived
induced pluripotent stem cells (“iPSCs”) and in mdx mice (which
have the same dystrophin mutation as human patients).15 Around the
same time, another research team demonstrated, for the first time, the
way in which CRISPR could be used to halt HIV-1 replication and
eliminate the virus from infected cells in animal models.16 With the
fast-moving development of the science, clinical trials are being
developed to treat diseases using somatic genome editing.17
The first somatic gene-editing clinical trials in the United States
occurred in 2017, when the first U.S. patient received an in vivo zinc
finger nucleases (“ZFNs”)-based editing therapy for Hunter
syndrome (mucopolysaccharidosis type II).18 Additional genomeediting trials using ZFNs are now open for other rare genetic
conditions, such as mucopolysaccharidosis I,19 hemophilia B,20 and βthalassemia.21

13. John Travis, Making the Cut: CRISPR Genome-Editing Technology Shows Its
Power, 350 SCIENCE 1456, 1456–57 (2015).
14. David Cyranoski, CRISPR Gene Editing Tested in a Person, 539 NATURE 479, 479
(2016).
15. Yu Zhang et al., CRISPR-Cpf1 Correction of Muscular Dystrophy Mutations in
Human Cardiomyocytes and Mice, 3 SCI. ADVANCES, no. e1602814, Apr. 12, 2017, at 1, 1.
16. Ramona Bella et al., Removal of HIV DNA by CRISPR from Patient Blood
Engrafts in Humanized Mice, 12 MOLECULAR THERAPY: NUCLEIC ACIDS 275, 275
(2018).
17. Martina C. Cornel et al., Moving Towards a Cure in Genetics: What Is Needed to
Bring Somatic Gene Therapy to the Clinic?, 27 EUR. J. HUM. GENETICS 484, 484 (2019).
18. Jocelyn Kaiser, A Human Has Been Injected with Gene-Editing Tools to Cure
His Disabling Disease. Here’s What You Need to Know, SCIENCE (Nov. 15, 2017, 6:00
PM),
https://www.sciencemag.org/news/2017/11/human-has-been-injected-gene-editingtools-cure-his-disabling-disease-here-s-what-you [https://perma.cc/6T23-TP49].
19. Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN)
Therapeutic
SB-318
in
Subjects
with
MPS
I,
CLINICALTRIALS.GOV,
https://clinicaltrials.gov/ct2/show/NCT02702115
[https://perma.cc/2T3W-4HH2]
(last
updated June 7, 2018).
20. Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic
SB-FIX
in
Subjects
with
Severe
Hemophilia
B,
CLINICALTRIALS.GOV,
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The discovery of the CRISPR-Cas9 system for genome editing,
and its application to human cells, has accelerated progress in genome
editing.22 The first U.S.-based CRISPR-Cas9 clinical trial began
recruiting cancer patients for an ex vivo approach in 2018.23 The
eagerly awaited results from these clinical trials will act as the first
indications of the safety and efficacy of CRISPR-Cas9 genomeediting approaches.24 Trials using both ZFNs and CRISPR-Cas9 gene
editing are in the pipeline for SCD.
II. SCD AND SOMATIC GENOME EDITING
As gene-editing technology advances, it becomes more likely
that a technique like CRISPR can be used to develop a cure for SCD.
This part provides an overview of SCD, the genome-editing-based
approaches being developed to treat it, and the reaction of the SCD
community to these new approaches.
A. Background of SCD
SCD is the most common monogenic disorder, caused by a
single-point mutation.25 This mutation is located in the sixth codon of

https://clinicaltrials.gov/ct2/show/NCT02695160
[https://perma.cc/7EUJ-3XER]
(last
updated Feb. 12, 2019).
21. A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of
Transfusion-Dependent
Beta-thalassemia
(TDT),
CLINICALTRIALS.GOV,
https://clinicaltrials.gov/ct2/show/NCT03432364?term=genome+editing&rank=6 [https://perma.cc/
UCS6-7VEE] (last updated Feb. 4, 2019).
22. Jennifer A. Doudna & Emmanuelle Charpentier, The New Frontier of Genome
Engineering with CRISPR-Cas9, 346 SCIENCE 1077, 1077 (2014).
23. NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T
Cells), CLINICALTRIALS.GOV, https://clinicaltrials.gov/ct2/show/NCT03399448 [https://perma.cc/
F6V6-YZLQ] (last updated Mar. 4, 2019).
24. See Mary Ellen Perry et al., Genome Editing to ‘Re-Write’ Wrongs, 17 NATURE
REVIEWS: DRUG DISCOVERY 689, 689–90 (2018). The range of potential applications
makes the results of particular interest:
The relative ease of targeting by interchangeable guide RNAs is likely to be
particularly important for rare monogenic diseases. There are thousands of such
diseases, and each can result from different mutations in different individuals.
Following the discovery of Cas9, researchers have identified homologues in other
species with improved properties, such as reduced size and increased specificity. In
addition, engineered versions of Cas9 and related proteins, including nuclease-free
versions of Cas9 coupled to DNA or RNA-modifying enzymes, have been
developed. Of note are base editors that can correct the most common diseasecausing single-base mutations without creating a double-strand break in DNA.
Id. at 689.
25. Frédéric B. Piel, Martin H. Steinberg & David C. Rees, Sickle Cell Disease, 376
NEW ENG. J. MED. 1561, 1561 (2017) [hereinafter Piel et al., Sickle Cell Disease].
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the β-hemoglobin subunit.26 SCD is “a group of inherited diseases . . .
characterized by mutations in the gene encoding the hemoglobin
subunit β (HBB).”27 Sickle erythrocytes, or red blood cells, can lead
to recurrent vaso-occlusive episodes that are the hallmark of the
disease.28
The burden of the disease is highest in sub-Saharan Africa;
however, the disease is also common in the Mediterranean basin,
the Middle East, and India.29 The prevalence is estimated to be
between 300,000 and 400,000 infants born globally each year, the
majority in sub-Saharan Africa.30 It is also estimated that 100,000
people in the United States live with the disease.31 Individuals living
with SCD with the same genotype can clinically present very
differently.32 Common complications are acute pain events, acute
chest syndrome, stroke, leg ulcers, priapism, and sickle cell
retinopathy.33 The disease burden on the body can result in end
organ damage.34
The number of individuals living with the disease is expected to
increase globally.35 In high-income countries, this increase reflects
migration36 and gains in life expectancy among affected persons in
these countries that result from health interventions such as newborn
screening, penicillin prophylaxis, pneumococcal immunization, and
education about disease complications.37 In many African countries,
where the frequency is the highest, the overall number of births is
expected to double between 2010 and 2050.38 Worldwide, the growth
in the number of babies born with the disease is expected to increase
26. Nicola Conran, Carla F. Franco-Penteado & Fernando F. Costa, Newer Aspects of
the Pathophysiology of Sickle Cell Disease Vaso-Occlusion, 33 HEMOGLOBIN 1, 1 (2009).
27. Gregory J. Kato et al., Sickle Cell Disease, 4 NATURE REVIEWS: DISEASE
PRIMERS, no. 18010, Mar. 15, 2018, at 1, 1.
28. Piel et al., Sickle Cell Disease, supra note 25, at 1565.
29. Kato et al., supra note 27, at 2.
30. Frédéric B. Piel et al., Global Burden of Sickle Cell Anaemia in Children Under
Five, 2010–2050: Modelling Based on Demographics, Excess Mortality, and Interventions,
10 PLOS MED., no. e1001484 July 2013, at 1, 4 [hereinafter Piel et al., Global Burden].
31. See Sickle Cell Disease, CENTERS FOR DISEASE CONTROL & PREVENTION,
https://www.cdc.gov/ncbddd/sicklecell/data.html [https://perma.cc/L54L-9CJC].
32. Kato et al., supra note 27, at 11.
33. Id. at 1, 3, 4.
34. Id. at 5.
35. Piel et al., Global Burden, supra note 30, at 4.
36. Stephan Lobitz et al., Newborn Screening for Sickle Cell Disease in Europe:
Recommendations from a Pan-European Consensus Conference, 183 BRIT. J.
HAEMATOLOGY 183, 648, 650 (2018).
37. Russell E. Ware et al., Sickle Cell Disease, 390 LANCET 311, 311 (2017).
38. Piel et al., Global Burden, supra note 30, at 4.
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by more than 30% by 2050.39 Currently, in low-income countries, 90%
of children with SCD do not survive to adulthood.40
The molecular basis of SCD has been studied for many years and
is well understood. While a cure exists in the form of hematopoietic
stem cell transplantation (“HSCT”), it can be difficult to find donor
matches.41 Furthermore, HSCT remains an expensive procedure with
the prospect of serious complications, such as graft versus host disease
(“GVHD”).42 The limitations of treatments and procedures like
HSCT combined with the devastating nature of SCD and documented
poor access to high-quality care, has sparked hope that the era of
gene editing and gene therapy will change the tide for patients who
have historically been disenfranchised by the biomedical system.43
Recent improvements in understanding the molecular pathways
controlling production of red blood cells and fetal-to-adult
hemoglobin switching offer new therapeutic options.44 Substantial
resources are being directed into discovering a gene-editing cure
using these new mechanisms.45 To this end, SCD may facilitate a
turning point for gene-editing and gene-therapy research.
B.

SCD and Genome Editing

There are two dominant genome-editing approaches under
current exploration for treatment of SCD.46 The first, described as
“[t]he holy grail of genome editing for the β-hemoglobinopathies[,] is
the correction of the β-globin mutation . . . .”47 Using CRISPR-Cas9 to
repair the β-globin gene, preclinical studies have successfully used a
viral approach to edit hematopoietic stem cells from patients with

39. Id.
40. AM. SOC’Y OF HEMATOLOGY, supra note 1, at 23.
41. Courtney D. Fitzhugh et al., Hematopoietic Stem Cell Transplantation for Patients
with Sickle Cell Disease: Progress and Future Directions, 28 HEMATOLOGY/ONCOLOGY
CLINICS N. AM. 1171, 1178 (2014).
42. Javier Bolaños-Meade & Robert A. Brodsky, Blood and Marrow Transplantation
for Sickle Cell Disease: Overcoming Barriers to Success, 21 CURRENT OPINION
ONCOLOGY 158, 158 (2009).
43. Katherine Bourzac, Erasing Sickle-Cell Disease, NATURE OUTLOOK: BLOOD,
Sept. 28, 2017, at S28, S30.
44. Selami Demirci, Naoya Uchida & John F. Tisdale, Gene Therapy for Sickle Cell
Disease: An Update, 20 CYTOTHERAPY 899, 899 (2018).
45. Edward J. Benz Jr., The Cure Sickle Cell Initiative: Catalyzing Progress via
Innovative Interfaces Between NIH, Patients, Academics, ASH, and the Private Sector,
HEMATOLOGIST, Nov.–Dec. 2018, at 1, 1.
46. Demirci et al., supra note 44, at 904.
47. Id.
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SCD in the lab.48 The researchers have also shown that they can
successfully transplant the repaired cells into blood stem cells of
mice.49
Figure 1. Genome Editing Approaches for SCD: Approach A

Approach A: Schematic of β-globin mutation correction using
CRISPR-Cas9. The correction is made by changing the single
nucleotide mutation thymine to adenine (T to A), which
changes glutamic acid to valine at codon 6 of the β-globin
(HBB) gene. (Image Credit: Darryl Leja, National Human
Genome Research Institute).
The second approach entails disrupting BCL11A, a region of the
DNA known to suppress the production of fetal hemoglobin, a form

48. Rasmus O. Bak, Daniel P. Dever & Matthew H. Porteus, CRISPR/Cas9 Genome
Editing in Human Hematopoietic Stem Cells, 13 NATURE PROTOCOLS 358, 358 (2018).
49. See, e.g., id. at 363; Mark A. DeWitt et al., Selection-Free Genome Editing of the
Sickle Mutation in Human Adult Hematopoietic Stem/Progenitor Cells, 8 SCI.
TRANSLATIONAL MED., no. 360ra134, Oct. 12, 2016, at 1, 1.
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of hemoglobin associated with reduced disease severity.50 In 1949,
Janet Watson and colleagues reported that the blood of infants with
SCD delayed sickling in comparison to the mothers’ blood.51 This was
later determined to be caused by the high levels of fetal hemoglobin
(“HbF”) in the infants’ blood.52 Genome-wide association studies
identified that the BCL11A gene variant was strongly associated with
modulating HbF levels.53 The BCL11A gene variant is a prime target
for genome editing.54 Research studies in mouse models have
established that perturbation of the BCL11A enhancer with gene
editing can result in HbF levels to clinically ameliorate the disease.55

50. Daniel E. Bauer et al., An Erythroid Enhancer of BCL11A Subject to Genetic
Variation Determines Fetal Hemoglobin Level, 342 SCIENCE 253, 254 (2013).
51. Janet Watson, Albert W. Stahman & Francis P. Bilello, The Significance of the
Paucity of Sickle Cells in Newborn Negro Infants, 215 AM. J. MED. SCI. 419 (1948),
reprinted in 3 OBSTETRICAL & GYNECOLOGICAL SURV. 819, 819 (1949).
52. C. Lockard Conley et al., Negro Families in Baltimore, 21 BLOOD 261, 278 (1963);
G. Stamatoyannopoulos et al., A New Form of Hereditary Persistence of Fetal Hemoglobin
in Blacks and Its Association with Sickle Cell Trait, 46 BLOOD 683, 683 (1975).
53. Bauer et al., supra note 50, at 253.
54. Stuart H. Orkin & Daniel E. Bauer, Emerging Genetic Therapy for Sickle Cell
Disease, 70 ANN. REV. MED. 257, 260 (2019).
55. Matthew C. Canver et al., BCL11A Enhancer Dissection by Cas9-Mediated in Situ
Saturating Mutagenesis, 527 NATURE 192, 196 (2015); Vijay G. Sankaran et al., Human
Fetal Hemoglobin Expression Is Regulated by the Developmental Stage-Specific Repressor
BCL11A, 322 SCIENCE 1839, 1839 (2008); Manuela Uda et al., Genome-Wide Association
Study Shows BCL11A Associated with Persistent Fetal Hemoglobin and Amelioration of
the Phenotype of β-thalassemia, 105 PNAS 1620, 1620 (2008).
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Figure 2: Genome Editing Approaches for SCD: Approach B

Approach B: Schematic of gene editing to control silencing the
BCL11A gene, a region of the DNA known to suppress the
production of fetal hemoglobin. The use of CRISPR-Cas9 to
disrupt BCL11A allows for the production of high levels of fetal
hemoglobin (HbF; hemoglobin F) in red blood cells. (Image
Credit: Darryl Leja, National Human Genome Research
Institute)
Besides these two novel approaches, other curative genetic
therapies are moving forward. Sickle cell ex vivo gene therapy,
inserting a normal, functional gene to replace an abnormal gene, can
modify an individual’s genome.56 In March 2017, Jean-Antoine Ribeil
and colleagues reported the results of the first SCD patient who
received this therapy in France, stating that the patient achieved
“complete clinical remission with correction of hemolysis and biologic

56. Orkin & Bauer, supra note 54, at 264.
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hallmarks of the disease.”57 In that study, a research team endeavored
to insert a functional β-globin into a patient’s hematopoietic stem
cells, ex vivo, through the use of a lentiviral vector.58 This
breakthrough, along with the decades of foundational study dedicated
to understanding the molecular basis underlying this disease, may
pave the path for SCD to lead the implementation of these new
technologies into clinical care.59
C.

Cure for SCD and Engagement of the Community

Disorders of the blood constitute an area of active gene-therapy
and gene-editing research currently underway.60 In January 2018, the
National Institutes of Health (“NIH”) launched a $190 million, sixyear research initiative to remove the implementation barriers of
somatic gene editing in clinical care.61 These endeavors include
improving current delivery mechanisms, genome editors, and assays
for testing the safety and efficacy of genome-editing tools.62 With this
program, the NIH hopes to accelerate the field and expedite the
translation of gene-editing treatments into meaningful clinical
applications.63 On September 13, 2018, the NIH launched a new
initiative to help speed the development of cures for SCD.64 Dr. Gary
H. Gibbons, director of NIH’s National Heart, Lung, and Blood
Institute (“NHLBI”), stated, “Our scientific investments have
brought us to a point where we have many tools available to correct
or compensate for the defective gene that causes [SCD]. We are now
ready to use these tools to speed up our quest for a cure.”65
With advancements in gene therapy and a potential genomeediting cure for SCD on the horizon, we are likely to witness a

57. Jean-Antoine Ribeil et al., Gene Therapy in a Patient with Sickle Cell Disease, 376
NEW ENG. J. MED. 848, 849 (2017).
58. Id. at 848.
59. Id. at 854.
60. See, e.g., Canver et al., supra note 55, at 196; DeWitt et al., supra note 49, at 9.
61. News Release, Nat’l Insts. of Health, NIH to Launch Genome Editing Research
Program (Jan. 23, 2018), https://www.nih.gov/news-events/news-releases/nih-launchgenome-editing-research-program [https://perma.cc/HV63-GWXD].
62. Francis Collins, Accelerating Cures in the Genomic Age: The Sickle Cell Example,
NIH: DIRECTOR’S BLOG (Dec. 11, 2018), https://directorsblog.nih.gov/2018/12/11/
accelerating-cures-in-the-genomic-age-the-sickle-cell-example/ [https://perma.cc/T8TE-58YH].
63. Id.
64. News Release, Nat’l Insts. of Health, NIH Launches Initiative to Accelerate
Genetic Therapies to Cure Sickle Cell Disease (Sept. 13, 2018), https://www.nih.gov/newsevents/news-releases/nih-launches-initiative-accelerate-genetic-therapies-cure-sickle-celldisease [https://perma.cc/564H-YYJ9].
65. Id.
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watershed moment for those living with this debilitating illness,
especially in light of SCD’s long history of neglect.66 Though the
disease was first described over a century ago,67 very little progress
has been made to advance affordable, accessible treatment for those
affected by SCD.68
Persaud, Bonham, and colleagues conducted a qualitative study
between April and December 2017 to engage the SCD community
and ascertain its views on gene-editing therapies.69 The study70
consisted of fifteen focus groups: six patient, six parent, and three
physician groups. Participants answered survey questions about their
views on gene editing and participation in future clinical trials.
The study examined the views of patients, parents, and
physicians within the SCD community and found that, broadly, all
three stakeholder groups expressed enthusiasm over a seemingly
overdue treatment that carries the potential to completely eradicate
SCD. One patient stated, “With me sitting here in pain right now . . .
if there’s something that can be done to heal that, then I’m for it.”
Another said, “I’m very optimistic. It’s another possible option for
sickle cell patients and unfortunately we don’t have many.” Despite
the community’s overall optimism, a number of reservations
regarding gene editing were reported, especially relating to equitable
access. “To have the sickle cell population move this forward and
then not have this available for them equally, would be extremely
traumatic to the community,” said one physician, especially when
examining the SCD community’s history of discrimination.
III. SCD AND SCT: A LEGACY OF DISCRIMINATION
The legacy of discrimination against the SCD community
provides a backdrop for understanding current attitudes and
apprehensions regarding inequitable access to a potential cure. After
providing some general thoughts on the value-harm tradeoff inherent
in knowing one’s sickle cell status, this part provides an overview of
the history of discrimination against those living with SCD and SCT
66. Collins, supra note 62.
67. Herrick, supra note 2, at 179 & cmt. a.
68. Keith Wailoo, Sickle Cell Disease – A History of Progress and Peril, 376 NEW
ENG. J. MED. 805, 805 (2017).
69. Anitra Persaud et al., A CRISPR Focus on Attitudes and Beliefs Towards Somatic
Genome Editing from Stakeholders Within the Sickle Cell Disease Community, GENETICS
MED. 1 (Dec. 24, 2019), https://www.nature.com/articles/s41436-018-0409-6.pdf [https://perma.cc/
BZ2M-HRW2].
70. For the remainder of this section, the study discussed is referring to the Persaud
and Bonham study.
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and spotlights three especially striking examples of that
discrimination: in the U.S. military, the workplace, and the provision
of medical care. It then considers how the potential for discrimination
continues.
A. The Clinical Benefit and Harm in Knowing One’s Sickle Cell
Carrier Status
SCT, the heterozygous inheritance for sickle hemoglobin,71 has
evolutionarily persisted throughout the world due to its protection
against severe malaria syndromes.72 “In the United States, between
2.5 to 3 million people live with SCT including an estimated 6% to
9% of the African American population and 0.01% to 0.07% of the
remaining population, primarily those of Arab, Southeast Asian,
Hispanic, and Mediterranean descent.”73 SCT affects an estimated 300
million individuals worldwide, “with a prevalence ranging from 2% to
30% in more than 40 countries.”74 Because of its prevalence, SCT
reproductive counseling has been identified as an important public
health campaign and testing has been suggested in various settings.75
SCT carriers can have children who are homozygous SCD, compound
heterozygous SCT, or not affected at all.76 Although SCT is generally
an asymptomatic carrier state and most individuals never have
complications, studies have reported potential clinical manifestations
of SCT.77
There are instances where screening and knowledge of one’s
SCT status are important for reproductive decisions and can help one
to take potentially life-saving measures, e.g., preventing dehydration
and overexertion in circumstances involving extremely challenging
71. Jelili Ojodu et al., Incidence of Sickle Cell Trait—United States, 2010, 63
MORBIDITY & MORTALITY WKLY. REP. 1155, 1155 (2014).
72. Steve M. Taylor, Christian M. Parobek & Rick M. Fairhurst,
Haemoglobinopathies and the Clinical Epidemiology of Malaria: A Systematic Review and
Meta-Analysis, 12 LANCET INFECTIOUS DISEASES 457, 457 (2012) (“Haemoglobin AS,
CC, and AC genotypes and homozygous and heterozygous α-thalassaemia provide
significant protection from severe malaria syndromes . . . .”).
73. Rakhi P. Naik et al., Clinical Outcomes Associated with Sickle Cell Trait, 169
ANNALS INTERNAL MED. 619, 619 (2018).
74. Id.
75. REG’L OFFICE FOR AFR., WORLD HEALTH ORG., SICKLE-CELL DISEASE: A
STRATEGY FOR THE WHO AFRICAN REGION 1 (2010), https://apps.who.int/iris/bitstream/
10665/1682/1/AFR-RC60-8.pdf [https://perma.cc/KF5L-YAMQ]; see also Althea M. Grant
et al., Public Health Implications of Sickle Cell Trait: A Report of the CDC Meeting, 41
AM. J. PREVENTATIVE MED. S435, S438 (2011).
76. REG’L OFFICE FOR AFR., WORLD HEALTH ORG., supra note 75, at 1.
77. Chika Duru, Out for Blood: Employment Discrimination, Sickle Cell Trait, and the
NFL, 9 HASTINGS RACE & POVERTY L.J. 265, 269–72 (2012).
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physical activity.78 In a controversial decision, the National Collegiate
Athletic Association (“NCAA”) decided in 2010 that Division I
student-athletes must be screened for SCT after a number of college
football players with SCT died, resulting in lawsuits against the
NCAA and the student-athletes’ universities.79 NCAA-mandated
testing was extended to Division II schools in 2012 and Division III
schools in the 2014–2015 academic year.80 A team of hematologists
and experts in SCD conducted a systematic review of the literature
from 1970 to 2018, finding only moderate evidence of risk of
exertional rhabdomyolysis81 in those with SCT in high-exertional
exercise settings but no sufficient evidence supporting the risk of
78. Vence L. Bonham, George J. Dover & Lawrence C. Brody, Screening Student
Athletes for Sickle Cell Trait — A Social and Clinical Experiment, 363 NEW ENG. J. MED.
997, 998 (2010).
79. Id. at 997. See generally Verdict and Settlement Summary, Lloyd v. William March
Rice Univ., No. C-2008-56506, 2009 WL 2462617 (Tex. Dist. Ct. June 29, 2009) (detailing
the settlement reached between parents of a deceased nineteen-year-old football player,
the university, and the NCAA after the player experienced a fatal acute exertional
rhabdomyolysis event associated with his SCT). In the Lloyd settlement, the NCAA
agreed to recommend SCT testing during all routine mandatory physicals for studentathletes at Division I institutions. Id.; Heather R. Quick, Note, Privacy for Safety: The
NCAA Sickle-Cell Trait Testing Policy and the Potential for Future Discrimination, 97
IOWA L. REV. 665, 667 (2012).
A Pennsylvania appellate court noted that failing to test athletes can create a
significant risk. See Hill v. Slippery Rock Univ., 138 A.3d 673, 680 (Pa. Super. Ct. 2016).
The Hill court considered a negligence claim brought by a deceased student-athlete’s
parents. Id. The parents in Hill claimed that “the university should have tested for SCT
before allowing students to join in athletics and that the NCAA’s failure to require
Division II schools to screen for SCT was negligent.” Id.; Matt Fair, Pa. Justices Snub
Appeal Over NCAA’s Place in Death Suit, LAW360.COM, https://www.law360.com/
articles/877516/pa-justices-snub-appeal-over-ncaa-s-place-in-death-suit [https://perma.cc/
RQY7-SWDB (dark archive)]. The Hill court held that an increased risk of harm
significant enough to support a negligence action can occur through a failure to act or a
“sin of omission,” and thus the parents sufficiently pleaded a negligence claim when they
alleged that the NCAA’s failure to test a student for SCT increased the risk of harm to
that student. Hill, 138 A.3d at 680. The Supreme Court of Pennsylvania denied the
NCAA’s Petition for Allowance of Appeal. Hill v. Slippery Rock Univ., 640 Pa. 598
(2017).
80. Susan L. Smith & Miriam Shuchman, Sickle Cell Screening of College Athletes:
Legal Obligations Fulfilled, Moral Obligations Lacking, 92 OR. L. REV. 1127, 1128 (2014).
Smith and Shuchman note that the American Society of Hematology does not support the
mandatory testing. Id. (citing Statement on Screening for Sickle Cell Trait and Athletic
Participation, AM. SOC’Y HEMATOLOGY (Jan. 26, 2012), https://www.hematology.org/
news/2012/7703.aspx [https://perma.cc/2NS4-U4NV]).
81. “Exertional rhabdomyolysis, a syndrome characterized by skeletal muscle
degeneration and muscle enzyme leakage, has been shown to occur in normal, healthy
individuals following strenuous exercise. In severe cases, this syndrome can result in renal
failure and sudden death.” Gary L. Harrelson, A. Louise Fincher & James B. Robinson,
Acute Exertional Rhabdomyolysis and Its Relationship to Sickle Cell Trait, 30 J. ATHLETIC
TRAINING 309, 309 (1995).
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sudden death.82 There is a continuing debate regarding the clinical
utility of testing student-athletes to prevent risk of clinical
complications.83
While testing and knowledge may be quite helpful to some with
SCT, both SCD and SCT have a long and complicated history with
health-care delivery and the law. A legacy of discrimination, a lack of
health-care resources, and a lack of research support are all a part of
the history of this disease. This past may impact the sickle cell
community’s willingness to embrace new advances in addressing the
disease and offer up their own bodies for research to solidify such
advances.
B.

Discrimination Against People Living with SCD and SCT

Since its discovery, SCD has “emerged and reemerged at the
intersection of a variety of medical, genetic, serological,
anthropological, personal, and administrative discourses on
whiteness, hybridity, tribes, and citizenship.”84 After his research
“transform[ed SCD] into the ‘first molecular disease,’” Dr. Linus
Pauling also astoundingly suggested a public health campaign
whereby SCT carriers would be tattooed on their foreheads so they
would be readily recognizable to one another “and avoid falling in
love, thereby reducing the incidence of the disease.”85 In 1959,
physician Lydia A. DeVilbiss advocated for “managing” SCD by
means of mandatory premarital blood testing, as was done at the time
for venereal diseases, implying “that both conditions fall within the
realm of governance and must be addressed not only at the level of
the individual sick body . . . but also at the level of the citizen, that is,
through government programs and with respect to its implications for
the society as a whole.”86
Some scholars assert that SCT—not the actual disease, SCD—
has served historically as a pretext for state government surveillance
of reproductive decisions of African Americans.87 For example, in the
1960s and 1970s, some community members contended that because
82. Naik et al., supra note 73, at 624–25.
83. Charlotte Baker et al., Implementation of the NCAA Sickle Cell Trait Screening
Policy: A Survey of Athletic Staff and Student-Athletes, 110 J. NAT’L MED. ASS’N 564, 565
(2018); see also Duru, supra note 77, at 271.
84. MELBOURNE TAPPER, IN THE BLOOD: SICKLE CELL ANEMIA AND THE
POLITICS OF RACE 3 (1999).
85. KEITH WAILOO, DYING IN THE CITY OF THE BLUES: SICKLE CELL ANEMIA AND
THE POLITICS OF RACE AND HEALTH 228 (2001).
86. TAPPER, supra note 84, at 92–93.
87. Id. at 106.
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medical professionals at government-sponsored genetic counseling
programs “work[ed] at the behest of the state, [they] were committed
more to eliminating blacks than to eradicating the disease.”88
By the 1970s, SCT carriers were denied educational
opportunities,89 as well as jobs with commercial airlines90 and
chemical companies,91 and were disqualified from entrance into
military academies.92 Carriers also faced challenges in obtaining
insurance.93 Throughout the United States, states enacted laws that
invaded the privacy of African Americans by mandating sickle cell
testing in a paternalistic and intrusive manner. In 1971, the
Massachusetts state legislature enacted a law that required blood tests
for both SCT and SCD before a child could attend school.94 Even
more invasive, the California legislature passed a law in 1971
permitting the state’s Public Health Department to require testing of
black citizens “whenever appropriate.”95 Instead of promoting
education and research for treatments, the laws passed brought
88. ALONDRA NELSON, BODY AND SOUL: THE BLACK PANTHER PARTY AND THE
FIGHT AGAINST MEDICAL DISCRIMINATION 133 (2011).
89. See, e.g., id. at 136 (describing the experience of a woman with sickle cell anemia
who was denied admission to a nursing program after administrators learned of her
medical condition).
90. TROY DUSTER, BACKDOOR TO EUGENICS 28 (2d ed. 2003) (“[A]lmost all of the
major airlines grounded or fired their employees with sickle-cell trait in the early and mid1970s.”). As of 2014, “the Federal Aviation Administration (FAA) does not require
screening for SCT, nor is SCT disqualifying for any class of FAA certificate.” Bryant J.
Webber & Catherine T. Witkop, Commentary, Screening for Sickle-Cell Trait at Accession
to the United States Military, 179 MIL. MED. 1184, 1186 (2014). Additionally, in the 2008
clinical practice guideline, the Aerospace Medical Association did not recommend a
universal screening for SCT for aviators. AM. SOC’Y OF AEROSPACE MED. SPECIALISTS,
CLINICAL PRACTICE GUIDELINE FOR SICKLE CELL DISEASE/TRAIT (2008),
http://www.asams.org/guidelines/Completed/NEW%20Sickle%20cell%20anemia.htm
[https://perma.cc/5MGE-RJJ4].
91. In 1980, the DuPont Company admitted to “routinely” conducting
preemployment blood screening of black candidates to determine SCT carrier status.
Richard Severo, Air Academy to Drop Its Ban on Applicants with Sickle-Cell Gene, N.Y.
TIMES (Feb. 4, 1981), https://www.nytimes.com/1981/02/04/us/air-academy-to-drop-its-banon-applicants-with-sickle-cell-gene.html [https://perma.cc/G2UM-M2JL]. While no data
showed that carriers were at special risk in the chemical workplace, DuPont maintained
that its screening was a service to employees, not a means for barring them from working.
Id.
92. TAPPER, supra note 84, at 121–22.
93. See Severo, supra note 91. In a report commissioned by the National Academy of
Sciences, the Committee for the Study of Inborn Errors of Metabolism stated “that
although [SCT] carriers paid more for insurance with nine out of twelve companies, their
mortality rates did not differ from those of blacks without the trait.” Id.
94. DUSTER, supra note 90, at 41.
95. Id. at 51. A California state regulation mandated sickle cell screening of all blacks
admitted to hospitals, regardless of reason for admission. Id. at 42.
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“minimal health implications, capricious targeting of youthful
carriers, and the associated stigmatization without treatment or
counseling.”96 These laws thus provided no benefit and allowed great
intrusion into the private lives of black Americans.
The October 1970 Journal of the American Medical Association
(“JAMA”) article authored by a white physician at Virginia
Commonwealth University, Robert B. Scott, “boosted sickle cell
anemia’s visibility” in mainstream medicine and brought national
attention to the disease.97 The article highlighted striking disparities
that existed in funding among genetic diseases.98 For example, data
from 1967 showed that diseases such as cystic fibrosis and muscular
dystrophy, found predominately in populations of European descent,
received nonpublic volunteer funding amounting to millions of
dollars, whereas sickle cell anemia received only $100,000, even
though all three diseases shared similar rates of incidence.99 Further,
at that time NIH-funded grants were reported to be less common for
SCD than other rare genetic conditions.100 Scott’s widely read JAMA
article is stated to have played a pivotal role in spurring politicians
who vied to be credited with meeting the neglected health needs of
black communities.101 In 1972, Congress passed and President Nixon
signed into law the National Sickle Cell Anemia Control Act, the first
major U.S. law focused on SCD.102 The law increased federal funding
exponentially to expand SCD programs that developed research and
educational materials relating to SCD;103 it also made receipt of
federal funding to states contingent upon sickle cell testing being
voluntary.104 In 1976, Congress passed a law requiring Veterans

96. Id. at 41.
97. NELSON, supra note 88, at 121.
98. Robert B. Scott, Health Care Priority and Sickle Cell Anemia, 214 JAMA 731, 731
(1970).
99. NELSON, supra note 88, at 124; Scott, supra note 98, at 731.
100. Id.
101. Id. at 123–25.
102. National Sickle Cell Anemia Control Act, Pub. L. No. 92-294, 86 Stat. 136 (1972)
(codified as amended in scattered sections of 29 and 42 U.S.C.).
103. Id. at 138.
104. 42 U.S.C. § 300(a) (2012). The law was enacted in response to widespread genetic
screening in the United States, purportedly aimed at exposing “poor health care systems
by identifying carriers of sickle cell anemia” and designed to identify individuals who
possessed the SCT, as well as SCD. Melinda B. Kaufmann, Genetic Discrimination in the
Workplace: An Overview of Existing Protections, 30 LOY. U. CHI. L.J. 393, 402 (1999); see
also id. at 402 n.65 (“[T]hese programs began with the best intentions, and were supported
by African American leaders until they realized that such measures ‘would be used to
stereotype and disadvantage the very people they sought to help.’”).
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Administration hospitals to maintain the confidentiality of records
relating to sickle cell anemia.105
In the 1970s, the African American community and
organizations, such as the Black Panthers, embraced a complex
agenda for genetic testing, prevention, care, and alleviation of the
disease.106 While stakeholders affiliated with the SCD and SCT
community had separate and sometimes divergent political
agendas,107 alleviating human suffering appears to have been the
common driving purpose behind efforts to bring recognition, funding,
and progress to treatment of SCD.108
By the 1990s, however, many SCD patients experienced barriers
to accessing comprehensive care and pain management.109 For
example, staff at hospital emergency rooms questioned the
authenticity of pain associated with SCD, some arguing that providing
pain relief for SCD community members would reward “drugseeking” behavior.110 This attitude enabled the narrative that those
suffering from SCD were “a variant of the inner city drug addict
stereotype.”111
The year 1995 marked the first year of many where federal
genetic discrimination legislation was introduced, and then
languished, in Congress.112 In 2000, testifying before the Senate
Committee on Health, Education, Labor, and Pensions, then Director
105. Veterans Omnibus Health Care Act of 1976, Pub. L. No. 94-581, § 111(a)(1), 90
Stat. 2842, 2849 (codified as amended at 38 U.S.C. § 7332(a)(1) (2012)).
106. NELSON, supra note 88, at 118–19. Founded in Oakland, California, in 1966, the
Black Panther Party’s primary mission included community service and health promotion
within the African American community. Id. at 1, 49.
107. Id. at 116, 148. Nelson argues that the Nixon administration’s interest in SCD was
“a calculated political strategy,” motivated by a desire for black American votes. Id. at
148. Nelson also asserts that the Black Panther Party used SCD as a proxy to spotlight
“the inequities of a profit-driven U.S. healthcare system sustained by publicly funded
biomedical research” and as a “powerful symbol of [the Party’s] affiliation with and
service to African American communities.” Id. at 116.
108. WAILOO, supra note 85, at 23 (contrasting the “compassion and awareness” the
political campaigns of the 1970s brought with the stigmatization of the disease in 1990s
politics); Roland B. Scott, Reflections on the Current Status of the National Sickle Cell
Disease Program in the United States, 71 J. NAT’L MED. ASS’N 679, 679 (1979) (describing
advances in sickle cell treatment as related to politics and pointing out that, as of the late
1970s, the advances were already at risk as sickle cell centers were already closing down).
109. Vani A. Mathur et al., Multiple Levels of Suffering: Discrimination in Health-Care
Settings Is Associated with Enhanced Laboratory Pain Sensitivity in Sickle Cell Disease, 32
CLINICAL J. PAIN 1076, 1076–77 (2016).
110. WAILOO, supra note 85, at 23.
111. Id.
112. See Rep. Louise Slaughter, Essay, Genetic Information Non-Discrimination Act,
50 HARV. J. ON LEGIS. 41, 49–55 (2013).
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of the National Human Genome Research Institute, Francis S.
Collins, warned of the potential for “insidious discrimination” that,
without protections in place, would undoubtedly grow from the
Human Genome Project’s successful decoding of 3.2 billion chemical
letters that make up the human genome.113 The African American
community already had suffered discrimination and neglect in matters
relating to work, health insurance, and the provision of medical care
on numerous bases, including SCD and SCT status.114 Community
members had legitimate concerns that population genetic testing may
expand discrimination.115
In 2003, President George W. Bush signed the Sickle Cell
Treatment Act (“SCTA”) into law as an amendment to the American
Jobs Creation Act.116 This law expanded community-based research
and treatment grants for SCD, including the SCD Treatment
Demonstration Program;117 in 2009, however, authorization for the
SCTA expired and there were no immediate laws enacted to
reauthorize funding for programs established under the SCTA.118
For decades there has been an ebb and flow of commitment to
the cause of those suffering from SCD. As noted earlier, in the late
1960s, when compared with private funding for diseases occurring at
rates comparable to SCD but primarily affecting white
communities—e.g., cystic fibrosis and muscular dystrophy—those
diseases garnered greater funding than what was raised for SCD.119
Laws and policies ostensibly intended to support research and
treatment of those affected by SCD often encountered, and continue
to encounter, obstruction from various fronts.120 While these actions
113. Genetic Information in the Workplace: Hearing before the S. Comm. on Health,
Educ., Labor, & Pensions, 106th Cong. (2000) (statement of Dr. Francis S. Collins,
Director of the National Human Genome Research Institute), 2000 WL 1115522.
114. See supra notes 90–93 and accompanying text.
115. Dorothy E. Roberts, The Nature of Blacks’ Skepticism About Genetic Testing, 27
SETON HALL L. REV. 971, 971–72 (1997).
116. American Jobs Creation Act of 2004, Pub. L. No. 108-357, § 712, 118 Stat. 1418,
1558–61 (codified as amended in scattered sections of 42 U.S.C.); see also Examining
Legislation to Improve Public Health: Hearing Before the Subcomm. on Health of the H.
Comm. on Energy & Commerce, 114th Cong. 32 (2016) (prepared statement of Sonja L.
Banks, President, Sickle Cell Disease Association of America) [hereinafter Examining
Legislation to Improve Public Health].
117. American Jobs Creation Act of 2004, § 712, 118 Stat. at 1558–61.
118. Examining Legislation to Improve Public Health, supra note 116, at 2.
119. Scott, supra note 98, at 731; see also NELSON, supra note 88, at 124 (outlining the
obvious racial implications of underfunding for SCD).
120. DUSTER, supra note 90, at 61–62. Over the years, other groups began demanding
federal funding for their own diseases, while others argued successfully for a single
comprehensive bill covering all disorders. Id. at 62.
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may not be deliberately aimed at marginalizing the SCD community,
the effect may be experienced as such. For example, passage of the
Sickle Cell Disease and Other Heritable Blood Disorders Research,
Surveillance, Prevention, and Treatment Act of 2018 highlights
Congress’s commitment to push forward with research that will
increase understanding of the “prevalence, distribution, outcomes,
and treatments associated with SCD.”121 This law was originally
drafted to exclusively focus on SCD; however, it was expanded before
passage to include other blood disorders.122 Still, the new law is
beneficial in that “[i]t also reauthorizes SCD prevention and
treatment grants awarded by the Health Resources and Service
Administration (HRSA), and it authorizes the Centers for Disease
Control and Prevention [(‘CDC’)] to award SCD surveillance grants
to states, academic institutions and nonprofit organizations.”123
Though progress has been made at the federal level, some state
laws specifically applicable to SCD remain on the books, and some of
these laws invade genetic privacy rights of patients and the parents of
those patients who have SCD or SCT.124 In other instances, laws not
121. The President Signs the Sickle Cell Treatment Act of 2018!, SICKLE CELL DISEASE
ASS’N AM., INC. (Dec. 19, 2018), https://www.sicklecelldisease.org/2018/12/19/thepresident-signs-the-sickle-cell-treatment-act-of-2018/ [https://perma.cc/WV5J-NQFK].
122. Compare Sickle Cell Disease Research, Surveillance, Prevention, and Treatment
Act of 2018, S. 2465, 115th Cong. (2018) (as proposed in Senate, Feb. 28, 2018), with Sickle
Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention,
and Treatment Act of 2018, S. 2465, 115th Cong. (2018) (proposed as an amendment in
the nature of a substitute in Senate, Aug. 15, 2018) (amending the bill to, in effect, reduce
the funds and available resources for SCD). The latter version was signed into law on
December 18, 2018. The President Signs the Sickle Cell Treatment Act of 2018!, supra note
121.
123. Id.
124. DUSTER, supra note 90, at 62 (“While the federal law eliminated compulsion, it
has also brought mass genetic screening into the sphere of routine public health activities.
Given the fact that many screening laws have not actually been repealed and that
compulsory screening programs might survive a court test, it is not frivolous to suggest
that the current popularity of voluntary laws is no guarantee that mandatory programs will
not someday be resumed.”). By 1987, newborn screening was again mandatory in seven
states. Id. As of 2007, routine state screening of newborns was universal throughout the
United States, and as of 2025, “nearly all individuals enlisting in the military should have
been previously screened.” KENNETH LIN & MARY B. BARTON, U.S. DEP’T OF HEALTH
& HUMAN SERVS., SCREENING FOR HEMOGLOBINOPATHIES IN NEWBORNS:
REAFFIRMATION UPDATE FOR THE U.S. PREVENTIVE SERVICES TASK FORCE 1 (2007),
https://www.ahrq.gov/downloads/pub/prevent/pdfser/sicklecelles.pdf [https://perma.cc/5647LXN9]; see also SEC’Y’S ADVISORY COMM. ON HERITABLE DISORDERS IN NEWBORNS &
CHILDREN, U.S. DEP’T OF HEALTH & HUMAN SERVS., SCREENING U.S. COLLEGE
ATHLETES FOR THEIR SICKLE CELL DISEASE CARRIER STATUS 11–13 (2010),
https://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/heritable-disorders/
reports-recommendations/reports/college-athletes-sickle-cell.pdf [https://perma.cc/
Z5SN-9D6B]; Webber & Witkop, supra note 90, at 1188.
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specifically focused on genetic information still play a critical role in
protecting individuals with manifested or diagnosed medical
conditions such as SCD.125 As discussed later in this Article, for these
individuals, federal protections under the Genetic Information
Nondiscrimination Act of 2008 (“GINA”) do not cover manifested or
diagnosed genetic diseases.126 Thus, case law specifically addressing
the rights of those with SCD—even cases dating back to the 1980s—
can be instructive and relevant in understanding current rights under
the law.
C.

Discrimination in the Military

Although the 1972 National Sickle Cell Anemia Control Act
curtailed state-ordered mandatory testing, controversial practices
based upon disputed scientific evidence continued to inform U.S.
military policies that discriminated against SCT carriers. Such policies
held that recruits with SCT would be barred from submarine service
in the U.S. Navy and from serving as air crew members in the U.S.
Army.127 The death of four black Army recruits out of approximately
four thousand between March 1968 and February 1969 at a moderate
altitude (>4060) training camp led the National Academy of Sciences
and National Research Council to request, and the U.S. Department
of Defense (“DoD”) to organize, a committee to investigate and
make recommendations.128 In 1970, the Military Aviation Safety
Subcommittee determined that data on clinical outcomes associated
with SCT carrier status were inadequate but nevertheless
recommended screening for both the trait and disease in all recruits
“regardless of race.”129 Additionally, the committee recommended
limitations on SCT carriers’ military activities, such as in “aviation,
diving, special forces [assignments] and high-altitude parachuting.”130
However well intentioned the committee’s recommendations were,

125. For examples of discrimination in the workplace and the use of ADA and section
504 of the Rehabilitation Act where the Genetic Information Nondiscrimination Act of
2008 would otherwise not have provided protection against discrimination of a manifested
genetic condition, see infra Section III.D.
126. See infra Section V.B.2.
127. Severo, supra note 91.
128. DUSTER, supra note 90, at 26–27; Mauricio De Castro et al., Genomic Medicine in
the Military, 1 GENOMIC MED., no. 15008, Jan. 13, 2016, at 1, 1; V.M. Voge, N.R. Rosado
& J.J. Contiguglia, Sickle Cell Anemia Trait in the Military Aircrew Population: A Report
from the Military Aviation Safety Subcommittee of the Aviation Safety Committee, AsMA,
62 AVIATION, SPACE & ENVTL. MED. 1099, 1100 (1991).
129. DUSTER, supra note 90, at 27; De Castro et al., supra note 128, at 2.
130. De Castro et al., supra note 128, at 2.
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the investigation lacked “essential controls and comparisons.”131
Though largely based on mere observation of frequencies—inviting
the hazard “of spurious relations and false conclusions”132—the
committee’s recommendations were implemented “by all branches of
the U.S. military in 1973.”133 At the time, many scientists and
physicians believed that restrictions relating to those carrying SCT are
“a senseless stigma and an unscientific suggestion that their genes are
somehow inferior.”134
1. U.S. Air Force Academy Prohibitions and Successful Challenge
Following the committee’s recommendations, the U.S. Air Force
(“USAF”) Academy adopted a policy of excluding blacks who
carried SCT.135 This policy was applied only to the elite Air Force
Academy—the Air Force Reserve Officers’ Training Corps
(“ROTC”) scholarship program did “not disqualify blacks from
general enlistment or from being commissioned.”136
Stephen Pullens, a former state champion high hurdler and foursport star athlete and mountain climber, passed the Air Force
Academy’s pilot qualifying exam, including a physical examination,
before reporting to the school in July 1979.137 After a blood test
revealed Pullens’s SCT carrier status, he was forced to leave the
Academy.138 The Air Force argued that it had legitimate interests in
screening future and current pilots for health problems.139 Sociologist
Troy Duster contends that the Air Force’s position that SCT-carrying
pilots would pose potential risks to others or would themselves
experience heightened risks indicates that Pullens’s dismissal
presented yet another instance of “appropriated genetic explanation”

131. DUSTER, supra note 90, at 27.
132. Id.
133. Voge et al., supra note 128, at 1100.
134. Severo, supra note 91.
135. DUSTER, supra note 90, at 28.
136. Air Force Academy Sued over Sickle Cell Policy, N.Y. TIMES (Jan. 4, 1981),
https://www.nytimes.com/1981/01/04/us/air-force-academy-sued-over-sickle-cell-policy.html
[https://perma.cc/9CMY-3624].
137. Id. The complaint cited to then-General Air Force Regulation 60-43, 5-11, which
stated that SCT carrier status would not disqualify an individual from entering military
service because those with the trait show no handicapping symptoms at altitudes above
10,000 feet or under physical stress, and rarely experience complications. Id. The
complaint alleged that Pullens was never tested to ascertain if he could handle such
stresses and that the Academy’s and Air Force’s regulations conflicted and denied due
process and equal protection of the law. Id.
138. Id.; see also DUSTER, supra note 90, at 28.
139. Severo, supra note 91.
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unsupported by research.140 In the context of numerous
discriminatory and stigmatizing actions taken in the name of
unproven dangers of SCT, the Air Force Academy screening policy
appeared to be “set up only to block, not to provide the grounds for
further empirical investigation.”141
In 1980, with support from the NAACP, Pullens sued the U.S.
Air Force in the U.S. District Court for the District of Minnesota.142
By early 1981, the case was settled, and the Air Force Academy
eliminated its ban on SCT-carrying airmen.143 A new policy made
“[c]andidates for the Air Force Academy who [had SCT] . . . eligible
for admission, provided they [were] otherwise medically qualified and
[met] the standard entrance requirements.”144 Pullens met all of the
requirements.145
2. Different Branches, Different Practices
In 1981, all U.S. military services permitted those with SCT to be
assigned to aviation duties with only limited restrictions.146 During
this time, the DoD required screening of all new service members but
only restricted the activities of those servicemen who tested as greater
than 41% sickle hemoglobin (“HbS”).147 Under the DoD directive,
the various branches undertook a number of different initiatives to
gather information, monitor, study, and compile and compare data
regarding SCT-carrying service members and control individuals.148
By 1985, “the DoD eliminated the [>41% HbS] cutoff,” removing all
restrictions for SCT carriers in occupational specialties.149
Again in the 1990s, after three USAF recruit deaths, the Armed
Forces Epidemiology Board revisited the possibility of specialty
restrictions for SCT carriers, recommended against SCT screening,
and instead recommended heat injury prevention.150 In 1996, the DoD
140. DUSTER, supra note 90, at 28.
141. Id. at 30.
142. Pullens v. U.S.A.F., No. 4-80 Civil 595 (D. Minn. July 21, 1981) (on file with the
North Carolina Law Review).
143. Severo, supra note 91.
144. Id. (reporting statements made by the Air Force Surgeon General, Lieutenant
General Paul W. Myers); see also Webber & Witkop, supra note 90, at 1185 (describing
the DoD’s policy that dropped the occupational restrictions on SCT service members and
also mandated SCT screening).
145. See Severo, supra note 91.
146. Voge et al., supra note 128, at 1100.
147. Webber & Witkop, supra note 90, at 1185.
148. Voge et al., supra note 128, at 1100–01.
149. Webber & Witkop, supra note 90, at 1185.
150. Id.
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updated Instruction 6465.1 to eliminate the mandated Hemoglobin S
testing for SCT in all military accessions.151 And yet, as of 2014, the
Air Force, Navy, and Marine Corps continued to “screen all
accessions for disqualifying hemoglobin disorders and mandat[ed]
dismissal of all individuals whose HbS concentration exceed[ed]
45%[, and although t]he Army selectively screen[ed] individuals
entering certain military occupational specialties (e.g., aviation,
diving, and special operations),” the Army did not “consider SCT a
disqualifying condition.”152 Practices at service academies have
continued to vary with no cohesive policies in place.153
The U.S. military’s approach to addressing SCT in recruits
clearly remains unsettled.154 A 1987 study found that SCT was
associated with a higher risk of exercise-related sudden death.155 A
2016 study of military recruits did not find an association between a
higher risk of exercise-related sudden death for those with SCT as
opposed to other recruits; it did find a significantly higher risk of
exertional rhabdomyolysis in recruits with the trait.156 A 2018
systematic review of the clinical literature found moderate evidence
that in high-exertional exercise settings there is a risk of exertional
rhabdomyolysis in those with SCT, but there is insufficient evidence
to support a risk of sudden death.157 The study stated that prospective
large-scale research studies to understand the clinical risk associated
with SCT are needed.158 Today, the need persists for research to
protect the safety of recruits with SCT and the development of
uniform service-wide policies based on rigorous empirical studies. As
reported in 2014,
[t]he USAF, Navy, and Marine Corps provid[ed] group-based
counseling for SCT+ recruits early in basic training, but
interventions differ[ed]: USAF recruits [would] wear a white
armband at all times throughout training; Navy recruits [would]
wear a red belt or red dog tag during exercise; and Marine
Corps recruits [were] not publicly identified.159
151. Id.
152. Id.
153. Id.
154. See De Castro et al., supra note 128, at 4.
155. John A. Kark et al., Sickle-Cell Trait as a Risk Factor for Sudden Death in Physical
Training, 317 NEW ENG. J. MED. 781, 781 (1987).
156. D. Alan Nelson et al., Sickle Cell Trait, Rhabdomyolysis, and Mortality Among
U.S. Army Soldiers, 375 NEW ENG. J. MED. 435, 436 (2016).
157. Naik et al., supra note 73, at 625.
158. Id.
159. Webber & Witkop, supra note 90, at 1185.
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While the military has a significant interest in quickly identifying
genetic traits of recruits for health and safety purposes,160 the
branches should be cognizant of potential discrimination.
D. Discrimination in the Workplace
Employees affected by discrimination or stigma based on actual
or perceived sickle cell status have attempted to assert their legal
rights. A few standout sickle cell cases have helped to raise awareness
of discriminatory practices and have been elevated to the national
stage for use in informing and shaping federal law and policy.
A seminal genetic discrimination case, Norman-Bloodsaw v.
Lawrence Berkeley Laboratory,161 considered whether an employee
“may, without [his/her] knowledge [or consent], be tested for highly
private and sensitive medical and genetic information,” such as SCT,
during a general employee physical.162 This case is frequently cited in
genetic discrimination literature and was specifically referenced in the
“Findings” section of GINA.163 As the first class action case alleging
discrimination and invasion of privacy in relation to genetic testing in
the workplace, Norman-Bloodsaw represents the reality of everyday
genetic discrimination in the workplace before passage of GINA, the
federal legislation intended to protect employees.164 The case is still
influential in circumstances where genetics protections under federal
and state law are lacking.165
In Norman-Bloodsaw, the employer was a federal contractor
with the U.S. Department of Energy, and the named defendants were
sued in both their official and individual capacities.166 All but one of
160. “The military has a legitimate interest in obtaining information about warfighters’
physical and mental abilities, including genomic information, but only if the genomic test
is a valid indicator of what it purports to show and the information is necessary in order to
carry out the mission.” De Castro et al., supra note 128, at 3.
161. 135 F.3d 1260 (9th Cir. 1998).
162. Id. at 1264.
163. 42 U.S.C. § 2000ff cmt. 4 (2012) (Legislative Findings) (“Congress has been
informed of examples of genetic discrimination in the workplace. These include the use of
pre-employment genetic screening at Lawrence Berkeley Laboratory, which led to a court
decision in favor of the employees in that case[.] Norman-Bloodsaw v. Lawrence Berkeley
Laboratory (135 F.3d 1260, 1269 (9th Cir. 1998)). Congress clearly has a compelling public
interest in relieving the fear of discrimination and in prohibiting its actual practice in
employment and health insurance.”).
164. Elizabeth Pendo, Race, Sex, and Genes at Work: Uncovering the Lessons of
Norman-Bloodsaw, 10 HOUS. J. HEALTH L. & POL’Y 227, 230 (2010).
165. Id. at 229 (“[G]enetic testing of workers occurs and is likely to continue even after
GINA, and the gathering and use of genetic information in the workplace is not neutral
and often exacerbates long-standing patterns of discrimination based on race and sex.”).
166. Norman-Bloodsaw, 135 F.3d at 1264.
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the plaintiffs were individuals who had “received written offers of
employment expressly conditioned upon a ‘medical examination,’
‘medical approval,’ or ‘health evaluation.’”167 In the process of
completing medical history questionnaires and providing blood and
urine samples, the plaintiffs were asked if they had any of sixty-one
medical conditions, including sickle cell anemia.168 Thereafter, blood
samples were tested for SCT, without notice or consent, and allegedly
this testing was only conducted on samples from black employees.169
In 1995 the plaintiffs obtained an Equal Employment
Opportunity Commission (“EEOC”) right-to-sue letter on behalf of
both past and present employees who were at any time subjected to
the testing at issue.170 Specifically, the plaintiffs alleged that the
defendants violated: (1) the Americans with Disabilities Act of 1990
(“ADA”) by “requiring, encouraging, or assisting in medical testing
that was neither job-related nor consistent with business necessity”;
(2) the constitutional right to privacy under both federal and
California law; and (3) “Title VII by singling out black employees for
[SCT] testing.”171 After the district court dismissed all claims, the
plaintiffs filed an appeal in the Ninth Circuit.172 Ultimately, the
appellate court affirmed the dismissal of the ADA claims but
reversed on the Title VII and the federal and state privacy claims
under the U.S. and California Constitutions.173
With regard to SCT, the appellate court stated that carrier status
pertains to “sensitive information about family history and
reproductive decision making,” and these were “aspects of one’s
health in which one enjoys the highest expectations of privacy.”174 The
appellate court further found that the alleged discrimination fell
“neatly into a Title VII framework,” namely that the plaintiffs had
alleged “that black . . . employees were singled out for additional
nonconsensual testing and that defendants thus selectively invaded
167. Id. at 1264–65. The employer represented that the program’s objectives were “to
protect employees from possible health hazards in their work environment; to assure
placement in work that can be performed in a reliable and safe manner; to promote early
detection, treatment and rehabilitation; and to apply preventative medical measures
toward the maintenance of good physical and mental health . . . .” Pendo, supra note 164,
at 232 (quoting Brief of Defendants–Appellees, Norman–Bloodsaw v. Lawrence Berkeley
Lab., 135 F.3d 1260 (9th Cir. 1998) (No. 96-16526), 1997 WL 33633545, at *9–10).
168. Norman-Bloodsaw, 135 F.3d at 1265.
169. Id.
170. Id.
171. Norman-Bloodsaw, 135 F.3d at 1265–66.
172. Id. at 1266.
173. Id. at 1275.
174. Id. at 1270.
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the privacy of certain employees on the basis of race.”175 Although the
district court held that the tests were not a condition of employment,
the Ninth Circuit found that, since “the preplacement exams were,
literally, a condition of employment,” the fact that the preplacement
exam tested black employees for SCT made it a condition of
employment.176
The parties reached a settlement in this case under which
Lawrence Laboratories paid $2.2 million to the plaintiffs.177 Further,
Lawrence Laboratories agreed to implement new procedures that
would prohibit employee testing without informed consent and
provide employees opportunities to review their medical records.178
Lawrence Laboratories also offered to expunge from the medical
records any testing information—positive or negative—relating to
SCT.179
Additionally, in Fleming v. State University of New York,180 a
plaintiff’s SCD became the center of employment litigation involving
an aspiring young doctor. Dr. Lester Fleming, an anesthesiologist, had
recently completed his residency at the State University of New York
(“SUNY”) and was seeking permanent employment at the Yuma
Regional Medical Center in Arizona (“Yuma”).181 After Yuma and
Dr. Fleming entered into an employment contract, Yuma began a
credentialing process that included inquiries with Dr. Fleming’s
former employers.182 During this process, the SUNY residency
program director disclosed Dr. Fleming’s SCD to Yuma.183 After
confirming this diagnosis with Dr. Fleming’s hematologist, Yuma
informed Dr. Fleming that he should seek employment elsewhere.184
Yuma modified Dr. Fleming’s employment offer, adding the
requirement that he sign an acknowledgement stating that, if he were
to fall ill, Yuma was not able to provide him a reasonable
accommodation for his operating room and call schedules.185 Dr.

175.
176.
177.
178.
179.
180.
181.
182.
183.
184.
185.

Id. at 1272.
Id.
Pendo, supra note 164, at 246.
Id.
Id.
502 F. Supp. 2d 324 (E.D.N.Y. 2007).
Id. at 327.
Id.
Id.
Id.
Id.

97 N.C. L. REV. 1093 (2019)

1122

NORTH CAROLINA LAW REVIEW

[Vol. 97

Fleming refused to sign the contract addendum and characterized the
added requirement as constructive termination in his lawsuit.186
The district court found merit in Dr. Fleming’s claim under
section 504(d) of the Rehabilitation Act because section 504 adopts
the ADA’s Title I provision that declares: “No covered entity shall
discriminate against a qualified individual with a disability because of
the disability of such individual in regard to job application
procedures, the hiring, advancement, or discharge of employees,
employee compensation, job training, and other terms, conditions,
and privileges of employment.”187 The defendants—Dr. Fleming’s
former employers—had described Dr. Fleming as a person suffering
from sickle cell anemia, thus classifying him as a person with a
disability; this classification, in turn, adversely affected his
opportunities to work as an anesthesiologist.188
Further, citing Second Circuit precedent, the district court
asserted that an individual’s constitutional right to privacy in his
health status protects information about “‘serious medical
condition[s],’ especially those that are likely to provoke . . .
‘discrimination and intolerance.’”189 Finding that sickle cell anemia is
such a disease with “the potential to provoke intolerance and
discrimination,” the court rejected SUNY’s contention that sickle cell
anemia “falls far short of the ‘excruciatingly private and intimate’
medical conditions that inevitably provoke ‘hostility and intolerance
from others.’”190 The court noted that, while there are few reported
cases of discrimination based on sickle cell anemia, “a history of such
discrimination exists”191 and found that Dr. Fleming’s Fourteenth
Amendment right to privacy in health information did, indeed, entitle
him to confidentiality regarding his sickle cell anemia.192
Two years later, Dr. Fleming was before the Ninth Circuit in his
lawsuit against Yuma.193 There, and in the underlying case, he alleged
186. Id.
187. Id. at 336.
188. Id. at 337.
189. Id. at 342 (first alteration in original) (quoting Doe v. City of New York, 15 F.3d
264, 267 (2d Cir. 1994)). While Doe involved the confidentiality of HIV status, the Fleming
court stated: “The holding of Doe thus plainly applies to [SCD], which, while arguably
less likely than HIV to provoke discrimination and intolerance, nonetheless may do so,
and indeed has done so in the past.” Id. at 345. The Fleming court also noted that malice
or bad intent in the disclosure of such private information was not a prerequisite to
establishing an actionable claim. Id.
190. Id.
191. Id. at 343.
192. Id.
193. Fleming v. Yuma Reg’l Med. Ctr., 587 F.3d 938 (9th Cir. 2009).
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that Yuma’s refusal to accommodate his operating and call schedules
due to his sickle cell anemia constituted a breach of employment
contract and disability discrimination in violation of the
Rehabilitation Act of 1973.194 The district court had granted Yuma’s
motion for summary judgment, finding that the Rehabilitation Act
was inapplicable.195 The Ninth Circuit reversed,196 and the Supreme
Court denied Yuma’s petition for writ of certiorari.197
E.

Discrimination in Provision of Medical Care

Avery v. County of Burke198 is an important example of how
status as a sickle cell carrier has been used to justify extreme,
unnecessary, and ill-informed decisionmaking in the provision of
medical care. In this case, the Fourth Circuit vacated the lower court’s
entry of summary judgment against a fifteen-year-old woman,
Virginia Ann Avery, who was told by state employees that she had
SCT and was then advised to undergo a sterilization procedure.199 The
state clinic’s nurses and doctor “told Avery and her mother that
because Avery had [SCT], childbirth would either immediately
endanger her life” or shorten it by “two or three years,”200 and that
pregnant women with SCT are more “susceptible to numerous
diseases.”201 Based on these representations, Virginia Avery and her

194. Id. at 940. Section 504(a) of the Rehabilitation Act of 1973 creates a private right
of action for individuals subjected to disability discrimination by any program or activity
receiving federal financial assistance. 29 U.S.C. § 794a(a)(2) (2012).
195. See Fleming, 587 F.3d at 940. Yuma had argued that it was not subject to
requirements of the Rehabilitation Act because the anesthesiologist position at issue was
that of an independent contractor. See id.
196. See id. at 939 (holding that section 504 of “the Rehabilitation Act [does in fact]
cover[] discrimination claims by an independent contractor”). Furthermore, the Ninth
Circuit found “[t]he Rehabilitation Act covers any ‘otherwise qualified individual’ who
has been ‘excluded from the participation in, or denied the benefits of, or . . . subjected to
discrimination under any program or activity receiving Federal financial assistance.’” Id. at
941–42 (second alteration in original) (quoting 29 U.S.C. § 794(a) (2012)). Thus, the Act
“covers ‘all of the operations’ of covered entities, not only those related to employment.”
Id. at 942 (quoting 29 U.S.C. § 794(b) (2012)).
197. Fleming v. Yuma Reg’l Med. Ctr., 561 U.S. 1006 (2010). As of 2019, Doctor
Fleming is a successful anesthesiologist practicing in the state of Virginia. Dr. Lester
Fleming, U.S. NEWS & WORLD REP., https://health.usnews.com/doctors/lester-fleming191363 [https://perma.cc/H298-8QU9 (staff-uploaded archive)].
198. 660 F.2d 111 (4th Cir. 1981).
199. Id. at 113.
200. Id. The Fourth Circuit observed that SCT “is the carrier gene state of sickle cell
syndrome which exclusively affects black people.” Id. (emphasis added). Additionally,
both nurses involved in “Avery’s sterilization testified that they had no special training in
handling sickle cell cases.” Id. at 115.
201. Id. at 113.
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mother consented to sterilization and a North Carolina state court
authorized the procedure.202 Subsequent to her sterilization,203 Avery
underwent additional testing that showed she did not have SCT.204
This case represents an example of paternalism, fear tactics, and
possibly deliberate malfeasance in order to control a black woman’s
reproductive choices.
Under 42 U.S.C. § 1983, Avery brought suit against the County
Board of Health and County Board of Social Services, alleging
violations of her Fourteenth Amendment rights of privacy and
procreation.205 She argued that “she was wrongfully sterilized because
she did not have [SCT] and because sterilization is not medically
recommended or proper, even when there has been a correct
diagnosis of the trait.”206 After having been pressured into submitting
to the sterilization procedure so she could not bear children, Avery’s
claims were dismissed by the U.S. District Court for the Western
District of North Carolina.207 The Fourth Circuit Court of Appeals
revived the case, stating, “It is not essential . . . [to] show that all
persons suspected of having [SCT] have been mistreated [by the
county]. It is enough that an identifiable group of people . . . is subject
to constitutional deprivations through the inaction of the boards.”208
The Avery case is just one more example of the legacy of
discrimination against those in the SCD and SCT community, as well
as those perceived as belonging to that community.
IV. COMMUNITY ENGAGEMENT IS VITAL IN PREVENTING
PERPETUAL HEALTH INEQUITIES
While SCT and SCD community members remain optimistic, the
legacy of discrimination informs and heightens their uneasiness and
apprehension about inequitable access to curative genetic treatments
that the community, by participating in human genome-editing
technology research, will have brought to fruition. As seen in the

202. Id.
203. Id. at 112.
204. Id.
205. Id.
206. Id.
207. Id.
208. Id. at 114 (citing Withers v. Levine, 615 F.2d 158, 161 (4th Cir. 1980), abrogated by
Moore v. Winebrenner, 927 F.2d 1312 (4th Cir. 1991)) (“North Carolina law required both
[the health and social services] boards to supervise their employees and to promulgate
guidelines and policies to protect the health and well-being of the citizens of the county.”).
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Persaud-Bonham study,209 members of the SCD community, their
families, and their physicians have voiced a concern that the SCD
community may participate in the clinical trials and then not benefit
equitably from advances in gene-editing technology.210 The National
Academies of Sciences, Engineering, and Medicine 2017 Report on
Human Genome Editing concluded that “extensive and inclusive
public participation should precede clinical trials for any extension of
human genome editing beyond treatment or prevention of disease or
disability.”211 The report further stated that “[p]ublic participation
should be incorporated into policy-making process[es] for human
genome editing and should include ongoing monitoring of public
attitudes, informational deficits, and emerging concerns about issues
surrounding ‘enhancement.’”212 This Article contends that public
engagement and opinions are required not just for use of genome
editing for enhancement and germline alterations but for treatment to
prevent or cure disease and lessen disabling consequences of disease.
Due in part to the uncertainty related to the long-term impact of
gene editing, and the legacy of discrimination experienced by the
SCD community, participants in the Persaud-Bonham study
emphasized the need for absolute transparency by government and
biomedical researchers with respect to the development of clinical
trials. Study participants all wanted the government and researchers
to respect the community’s views and to meaningfully engage the
community in the development of clinical trials. A patient in the study
articulated this point, stating: “We need a seat at the table. When this
clinical trial is going on and you’ve got the researchers setting up
protocols, setting up how it is going to work—advocacy, [Community
Based Organization] . . . people that have sickle cell, need to be
involved in every aspect of the trial.”
In some respects, the study participants provided strategies for
how these goals could be met, including (1) partnerships with brokers
of trust within the community, (2) development of clear and effective
educational tools, (3) dissemination of information relevant to the
prospective participants through social media and other commonly
used communication platforms, and (4) a commitment to dedicating
resources to advance the treatment and care of SCD patients
209. Persaud et al., supra note 69, at 7. In this section, further discussion of “the study”
also refers to the Persaud-Bonham study. See supra Section II.C.
210. See supra Section II.C.
211. See NAT’L ACADS. OF SCIS., ENG’G, & MED., supra note 5, at 178 (emphasis
added).
212. Id.
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regardless of whether the fruits of gene editing come to bear.
Physicians, on the other hand, stressed being clear about the
limitations of gene editing, avoiding both explicit and implicit
coercion, and walking the path carefully to prevent further alienation
of the community. One physician offered the following comments:
I would say don’t mess it up . . . if you are really talking about it
impacting the sickle cell population, you have to be very careful
that the other rare diseases that have more resources don’t take
it over and the sickle cell population gets left in the dust. [Sickle
cell patients] have been left in the dust with so many other
things that they already are skeptics.
All three stakeholders—patients, parents, and physicians—were
concerned that access to gene-editing treatments in the future would
comprise a huge impediment to care and warned against using the
community as a means to an end.
Systematic public engagement of the disease communities in
developing gene-editing clinical trials and public education resources
is necessary. This engagement should not be limited to the most
controversial uses of the new technology, e.g., germline gene editing
or genetic enhancement; it is equally essential for uses related to
somatic gene editing for treatment and prevention of disease. The
equitable access to curative genetic therapies—like gene therapy and
gene editing—requires public input to guide public policy. Especially
when the disease—like SCD—is surrounded by a history of abuse and
neglect.
V. LEGAL PROTECTIONS OF INDIVIDUALS’ GENETIC INFORMATION
Though the SCD and SCT community has experienced ongoing
discrimination, Congress has endeavored to create meaningful
protections. This section considers GINA and the protections, and
lack thereof, which it provides to the historically undermined and
marginalized SCD and SCT community. Prior to GINA’s enactment,
there were up to 500 documented cases of genetic discrimination in
the United States.213 Without a law specifically guarding against this
discrimination, laws such as Title VII of the Civil Rights Act of
1964,214 the Americans with Disabilities Act of 1990,215 section 504 of

213. Ifeoma Ajunwa, Genetic Data and Civil Rights, 51 HARV. C.R.-C.L. L. REV. 75,
77–78 (2016).
214. With all the protections Title VII affords, this law makes no mention of genetic
information or health information. See Slaughter, supra note 112, at 47.
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the Rehabilitation Act of 1973, and the Health Insurance Portability
and Accountability Act of 1996 (“HIPAA”)216 sometimes provided
recourse and remedies for those suffering from discrimination based
on genetic information or disease. However, when these earlier
federal employment, antidiscrimination, and health-care privacy laws
were enacted, the potential for genetic knowledge and the
discriminatory implications and ramifications of genetic testing could

215. Carriers of genetic mutations who do not have or exhibit a symptomatic disorder
are not explicitly covered by the ADA. Slaughter, supra note 112, at 47–48. A 1995
Guidance issued by EEOC advised employers to refrain from taking action against
otherwise healthy employees and applicants based on the presence of genetic mutations
that may have predisposed the employee or applicant to disease. Id. at 48. But guidance is
just that—guidance, not law. See id. Still, guidelines do “constitute a body of experience
and informed judgment to which courts and litigants may properly resort for guidance.”
Skidmore v. Swift & Co., 323 U.S. 134, 140 (1944).
Unlike Title VII and the ADA, GINA lacks a disparate impact liability provision. See
42 U.S.C. § 2000ff-7(a)–(b) (2012) (recognizing that allegations of disparate impact on the
basis of genetic information does not establish cause of action under GINA); 29 C.F.R.
§ 1635.5(b) (2018); Ajunwa, supra note 213, at 84. However, this could change because,
though GINA was not intended to address specific protected classes, under 42 U.S.C.
§ 2000ff-7(b), GINA requires that
[o]n the date that is 6 years after May 21, 2008, there shall be established a
commission, to be known as the Genetic Nondiscrimination Study Commission
(referred to in this section as the “Commission”) to review the developing science
of genetics and to make recommendations to Congress regarding whether to
provide a disparate impact cause of action under this Act.
§ 2000ff-7(b). This should have occurred in May 2014, but it still has not. Ajunwa, supra
note 213, at 86–87, 87 n.74. Ajunwa suggests that the increased protection afforded by
disparate impact theory is needed to extend GINA’s reach where a plaintiff is unable to
obtain “actual evidence of genetic discrimination.” Id. at 105. Ajunwa offers the following
four reasons that support addition of a disparate impact clause to GINA:
(1) [the] theory . . . is in line with the precedent set by prior employment
discrimination laws; (2) the EEOC has declared that proof of deliberate
acquisition of genetic information is not necessary to establish a violation of
GINA, and proof of intent to discriminate likewise should not be required to
demonstrate genetic discrimination; (3) ease of access to genetic testing and the
insecurity of genetic information has increased the likelihood of genetic
discrimination in employment; and (4) real world instances of genetic testing have
shown that facially neutral testing may result in racial disparities.
Id. at 100.
216. HIPAA prohibits health insurance companies from assessing higher premiums for
unwell individuals within an employer-sponsored group policy, or from excluding
preexisting conditions; however, the group as a whole can be charged higher premiums.
See Slaughter, supra note 112, at 48. Therefore, there is a disincentive for employers to
hire potential employees who might be perceived as more likely to need medical care
and/or to be carrying genetic mutations. See Ajunwa, supra note 213, at 89. This
disincentive may work against women of childbearing age, older workers, and those who
fit race-based assumptions about health conditions such as SCT and SCD.
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not be fully envisioned.217 GINA’s drafters incorporated instructions
to close certain gaps in protections.218 For example, as required by
GINA, 2013 revisions to the HIPAA Privacy Rule added that genetic
information is Protected Health Information (“PHI”) covered by the
Privacy Rule, to the extent that such information is individually
identifiable.219 Further, HIPAA-covered entities may not use or
disclose protected genetic information for underwriting purposes.220
The Patient Protection and Affordable Care Act of 2010 (“ACA”)
filled additional gaps, and as of January 1, 2014, patients with
preexisting conditions, like SCD, could no longer be denied health
insurance coverage.221 In addition, prophylactic measures such as
pneumonia and influenza vaccinations—which are important for
people living with SCD—are currently covered as preventative
services.222 However, if successful, recent attempts to dismantle the
ACA will undo the law’s preexisting conditions protections.223
A. The Need for Protections Spurs GINA
In the 1990s, genomic science was growing exponentially. As
scientists, policymakers, and legislators realized the obvious clinical
relevance of genomic medicine, they also understood that research
participation by individuals to benefit our collective health would be
met by fear that genetic research study participants would
subsequently encounter genetic discrimination in the health insurance
217. Slaughter, supra note 112, at 42.
218. Id. at 42, 48.
219. 45 C.F.R. § 164.502(a)(5)(i) (2018).
220. Privacy in Genomics, NIH: NAT’L HUM. GENOME RES. INST. (Apr. 21, 2015),
https://www.genome.gov/27561246/privacy-in-genomics/ [https://perma.cc/5Q98-SABK]. No
such restrictions attach to the use or disclosure of PHI that has been de-identified. Id. Deidentification is often impermanent, due to insufficient proactive protections, and the
documented ability of computer science hackers to re-identify previously de-identified
information. Mats G. Hansson et al., The Risk of Re-Identification Versus the Need to
Identify Individuals in Rare Disease Research, 24 EUR. J. HUM. GENETICS 1553, 1553
(2016).
221. Patient Protection and Affordable Care Act, 42 U.S.C. § 18001(a), (d) (2012).
222. Cara V. James, On the Path to Health Equity: Improving the Quality of Sickle Cell
Disease Care, CMS.GOV: CMS HEALTH EQUITY BLOG (Sept. 22, 2016),
https://www.cms.gov/About-CMS/Agency-Information/OMH/about-cms-omh/blog/sickle-celldisease-care.html [https://perma.cc/FVV4-CA5Z].
223. Laura Hercher & Anya E.R. Prince, Gene Therapy’s Field of Dreams: If You
Build It, Will We Pay?, 97 N.C. L. REV. 1463, 1491 (2019). A recent victory for those who
oppose the ACA came in Texas v. United States, 340 F. Supp. 3d 579 (N.D. Tex. 2018),
when the Northern District of Texas issued a decision declaring the ACA
unconstitutional. Id. at 619. Sixteen states and the District of Columbia, intervenors in the
action, have appealed and continue to defend the ACA. Notice of Appeal at 1–2, Texas v.
United States, 340 F. Supp. 3d. 579 (N.D. Tex. 2018) (No. 4:18-CV-00167-O).
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sector and the workplace.224 In fact, 92% of Americans were
concerned that results of genetic testing might be used for harmful
purposes.225 Despite the uncertainty and complexity of genetic testing,
some employers and health insurers perceived a benefit from
obtaining genetic information.226 Reforms were urgently needed to
address citizens’ concerns about the real threats of workplace and
health insurance discrimination.227 Senator Edward Kennedy, a GINA
cosponsor in the Senate, aptly stated: “Discrimination in health
insurance and the fear of potential discrimination threaten both
society’s ability to use new genetic technologies to improve human
health and the ability to conduct the very research we need to
understand, treat, and prevent genetic disease.”228
As researchers worked to harness the potential of genetic
medicine to improve understanding of diseases and develop new,
personalized treatments, legislators began efforts to craft protections
against genetic discrimination.229 In deliberating the need for a federal
law that would protect private citizens from genetic discrimination,
Congress considered evidence of targeted genetic discrimination
against individuals in minority populations who carried genes
associated with a specific genetic disease or risk; SCD among African
Americans was one such disease.230 After years of diligence and
224. See Kathy L. Hudson, M.K. Holohan & Francis S. Collins, Keeping Pace with the
Times – The Genetic Information Nondiscrimination Act of 2008, 358 NEW ENG. J. MED.
2661, 2661, 2663 (2008); see also Protecting Workers from Genetic Discrimination: Hearing
Before the Subcomm. on Health, Emp’t, Labor & Pensions of the H. Comm. on Educ. &
Labor, 110th Cong. 33 (2007) [hereinafter Protecting Workers from Genetic
Discrimination] (prepared statement of Karen H. Rothenberg, Dean and Marjorie Cook
Professor of Law, University of Maryland School of Law) (“The tremendous promise of
genomics is hamstrung by fear.”); Kathy L. Hudson, Prohibiting Genetic Discrimination,
356 NEW ENG. J. MED. 2021, 2022 (2007) (explaining that fear of genetic discrimination
also stymied patients’ willingness to undergo genetic tests recommended by their
physicians or have results of such tests included in their medical records).
225. Protecting Workers from Genetic Discrimination, supra note 224, at 11 (prepared
statement of the Hon. Louise McIntosh Slaughter).
226. Slaughter, supra note 112, at 44; see also Genetic Non-Discrimination: Examining
the Implications for Workers and Employers: Hearing Before the Subcomm. on Emp’rEmp. Relations of the H. Comm. on Educ. & the Workforce, 108th Cong. 71 (2004)
[hereinafter Genetic Non-Discrimination] (statement of National Workrights Institute)
(“In a 2001 survey of U.S. firms almost 2% were currently conducting genetic tests for
Sickle Cell and Huntington’s Disease, 14% were acquiring genetic information during
workplace susceptibility testing and 20% reported requesting family medical histories
containing information on the likelihood of disease.”).
227. See Hudson et al., supra note 224, at 2661.
228. Id. at 2662.
229. See id.
230. Expert Report of Paul A. Lombardo at 4, Lowe v. Atlas Logistics Grp. Retail
Servs., No. 1:13-cv-02425-AT (N.D. Ga. June 5, 2015), ECF No. 70.
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determination, GINA was signed into law by President George W.
Bush.231 Senator Edward Kennedy proclaimed GINA “the first major
new civil rights bill of the new century.”232
B.

GINA’s Protections

GINA’s purpose is to “‘establish[] a . . . uniform . . . standard’ of
unacceptable use of genetic information . . . ‘to fully protect the public
from discrimination and allay their concerns about the potential for
discrimination, thereby allowing individuals to take advantage of
genetic testing, technologies, research, and new therapies.’”233 GINA
has two major parts. Title I, which prohibits genetic discrimination in
health insurance, applies to employer-sponsored group health plans,
health insurance issuers in group and individual marketplaces,
Medigap insurance, and state and local nonfederal government
plans.234 Title I expressly bans use or disclosure of genetic information
for underwriting purposes but does not mandate coverage of any
particular genetic test or treatment and does not prohibit medical
underwriting based on current health status.235 Title II of GINA
231. Prior to GINA’s passage, by Executive Order signed by President Clinton, federal
agencies were prohibited from discriminating against job applicants and employees based
on genetic information. See generally Exec. Order No. 13,145, 65 Fed. Reg. 6877 (Feb. 10,
2000). Dating back at least to 2001, President George W. Bush also supported legislation
to end unfair genetic discrimination, stating:
Genetic discrimination is unfair to workers and their families. It is unjustified—
among other reasons, because it involves little more than medical speculation. A
genetic predisposition toward cancer or heart disease does not mean the
condition will develop. To deny employment or insurance to a healthy person
based only on a predisposition violates our country’s belief in equal treatment
and individual merit.
The President’s Radio Address, 37 WEEKLY COMP. PRES. DOC. 963 (June 23, 2001).
232. Ben Feller, Bush Signs Anti-Discrimination Bill [GINA], CTR. FOR GENETICS &
SOC’Y
(May
21,
2008),
https://www.geneticsandsociety.org/article.php?id=4096
[https://perma.cc/SLY6-GN2S].
233. Lowe v. Atlas Logistics Grp. Retail Servs. (Atlanta), LLC, 102 F. Supp. 3d 1360,
1367 (N.D. Ga. 2015) (first alteration in original) (emphasis added).
234. Slaughter, supra note 112, at 56.
235. Id. HHS Standards for Privacy of Individually Identifiable Health Information,
known as medical privacy regulations, provide protections against use and disclosure of all
individually identifiable genetic information, but those regulations allow “use” of health
information for insurance underwriting purposes. 45 C.F.R. §§ 160.103, 164.502 (2018).
GINA also amended the Employee Retirement Income Security Act of 1974. 29 U.S.C.
§ 1191b(d)(6)(B) (2012) (clarifying that protected genetic information includes “requests
for, or receipt of genetic services, or participation in clinical research that includes genetic
services by [an employee] or any family member [of the employee]”). The Public Health
Service Act, Internal Revenue Code of 1986, and Title XVIII of the Social Security Act
are also amended by GINA. Slaughter, supra note 112, at 56. Under GINA, health
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makes it illegal to discriminate against employees or job applicants
based on genetic information.236 The Department of Labor, the
Department of Health and Human Services (“HHS”), and the
Treasury Department have joint power to promulgate and enforce
regulations relating to health insurance under GINA’s Title I.237 The
EEOC oversees GINA’s Title II, which relates to employment
discrimination.238 Under 42 U.S.C. § 2000ff-10, the EEOC
promulgated a rule codified at 29 C.F.R. § 1635;239 the GINA rule
defines “genetic test” with the exact language from the statute.240 The
regulation goes further, though, and provides specific examples of
genetic testing, including: “[c]arrier screening for adults using genetic
analysis to determine the risk of conditions such as . . . sickle cell
anemia.”241 The regulation notes that the list is not intended to be
exhaustive.242
1. GINA and SCD
As stated earlier, sickle cell anemia was among the first singlegene mutations identified.243 In the 1970s, African Americans had
been targeted for genetic testing for SCD and SCT. Their test results
were not held in confidence, and stigmatization and discrimination in
employment and health insurance coverage ensued.244 SCD has
become a “racialized” genetic disease in that it has been cast as
insurance issuers are prohibited from adjusting premiums or contribution amounts for
group coverage on the basis of genetic information. 29 U.S.C. § 1182(b)(3)(A) (2012). And
group health plans and health insurers are prohibited from denying coverage to a healthy
individual or charging that individual higher premiums based solely on a genetic
predisposition to specific diseases. Id. § 1182(b)(1). Further, Title I applies to data relating
to genetic information in the context of family history and prohibits a health insurer from
requesting or requiring participants to undergo genetic testing. 42 U.S.C. § 2000ff-1 (2012).
236. Id. Hiring, firing, job assignments, and promotions are examples of areas where
genetic information discrimination is prohibited, and the bill extends beyond employers to
include unions, employment agencies, and labor-management training programs.
Slaughter, supra note 112, at 57.
237. See Genetic Information Nondiscrimination Act of 2008, Pub. L. No. 110-233,
§ 106, 122 Stat. 881, 905 (codified as amended in scattered sections of 42 U.S.C.).
238. See 42 U.S.C. § 2000ff-10 (2012).
239. See 29 C.F.R. § 1635.3(f)(1) (2018).
240. “[G]enetic test” is defined as “an analysis of human DNA, RNA, chromosomes,
proteins, or metabolites that detects genotypes, mutations, or chromosomal changes.” 42
U.S.C. § 2000ff(7)(A) (2012); § 1635.3(f)(1).
241. 29 C.F.R. § 1635.3(f)(2) (2018) (emphasis added).
242. Id.
243. See Slaughter, supra note 112, at 43.
244. See Hearing: Genetic Non-Discrimination, supra note 226, at 107–08 (statement of
Karen H. Rothenberg, Dean and Marjorie Cook Professor of Law, University of
Maryland School of Law); see also Slaughter, supra note 112, at 45.
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belonging to a particular race, contrary to fact and science.245
Therefore, with genetic variants like those present in SCT and SCD,
concerns about discrimination are heightened. For this reason, GINA
specifically names carriers for sickle cell anemia in its “Findings”
section:
[M]embers of a particular group may be stigmatized or
discriminated against as a result of that genetic information.
This form of discrimination was evident in the 1970s, which saw
the advent of programs to screen and identify carriers of sickle
cell anemia . . . . State legislatures [enacted] discriminatory laws
. . . and in the early 1970s began mandating genetic screening of
all African Americans for sickle cell anemia, leading to
discrimination and unnecessary fear.246
2. GINA’s Limitations
As noted above, GINA has been described as the first civil rights
legislation of the twenty-first century. Yet concern continues that
genetic information will be used to “violate the privacy that surrounds
familial relationships and medical care.”247 A number of studies
document that underrepresented groups in research still have
heightened concerns regarding privacy, including control over their
genetic information.248
Despite the “Findings” section’s reference to the SCD and SCT
community’s experienced legacy of discrimination, GINA does not
provide protection to those with genetic diseases, including SCD. For
example, an individual’s diagnosed disease, disorder, or pathological
condition, or any signs or symptoms of such conditions, are not
covered genetic information under GINA, even if that condition has a
genetic basis.249 GINA restricts its definition of “genetic test” to
245. Ajunwa, supra note 213, at 86.
246. 42 U.S.C. § 2000ff cmt. 3 (Legislative Findings) (emphasis added).
247. Expert Report of Paul A. Lombardo, supra note 230, at 3.
248. Ellen W. Clayton et al., A Systematic Literature Review of Individuals’
Perspectives on Privacy and Genetic information in the United States, 13 PLOS ONE, no.
e0204417, Oct. 31, 2018, at 1, 12.
249. See 42 U.S.C. § 2000ff-9 (2012); 29 C.F.R. § 1635.12(a) (2018); Ajunwa, supra note
213, at 94. A disease, disorder, or pathological condition is considered “manifested” if the
individual “has been or could reasonably be diagnosed with the disease, disorder, or
pathological condition by a healthcare professional.” 29 C.F.R. § 1635.3(g) (2018). A
disease, disorder or pathological condition is not considered manifested “if the diagnosis is
based principally on genetic information.” Id. Health insurance regulations similarly have
defined “manifestation.” Anya E.R. Prince & Benjamin E. Berkman, When Does an
Illness Begin: Genetic Discrimination and Disease Manifestation, 40 J.L. MED. & ETHICS
655, 661 (2012). Though GINA does not cover a condition’s diagnosis or signs or

97 N.C. L. REV. 1093 (2019)

2019]

SOMATIC GENOME EDITING

1133

analysis of human DNA, RNA, chromosomes, proteins, or
metabolites that detect genotypes, mutations, or chromosomal
changes.250 However, it does not prohibit other widely used tests, for
example, those that measure complete blood counts, cholesterol, or
liver function.251 This creates a “gray area for discrimination,” as a
simple blood test may be used to detect genetic diseases like SCD.252
Furthermore, GINA does not protect “analys[e]s of proteins or
metabolites that are directly related to a manifested disease, disorder,
or pathological condition that could reasonably be detected by a
health care professional with appropriate training and expertise in the
field of medicine involved.”253 Also, an employer does not violate
GINA by using, acquiring, or disclosing medical information “that is
not genetic information about a manifested disease, disorder, or
pathological condition of an employee or member,” even if the
disease, disorder, or pathological condition has or may have a genetic
basis or component.254 These deficiencies give rise to calls by some
scholars for a disparate impact theory of protection under GINA,
which “would allow plaintiffs to show a pattern of employers turning
away individuals known [or believed] to carry such genetic diseases
from employment,” even if the employer had not subjected the
potential employee to testing deemed to be “genetic testing” under
GINA’s stringent definition.255
One of its principal sponsors in the House viewed GINA as “an
important step towards freedom from insidious discrimination,” but
the effort is by no means finished.256 And “[j]ust as access to all civil
symptoms of that diagnosis, the EEOC has made clear that such information is still subject
to other laws that regulate the acquisition and use of medical information, such as Title I
of the ADA. Id. at 661.
250. 29 C.F.R. § 1635.3(f)(3) (2018).
251. Id.; Ajunwa, supra note 213, at 94.
252. Ajunwa, supra note 213, at 94. These holes in protection expose individuals to
“covert genetic discrimination.” Id.
253. Id. (alteration in original).
254. 29 C.F.R. § 1635.12(a) (2018) (emphasis added).
255. Ajunwa, supra note 213, at 94. But see Duru, supra note 77, at 286–87 (“M]any
judges remain hostile towards the disparate impact theory of liability, which is unlikely to
survive many more court challenges.”).
256. Slaughter, supra note 112, at 59. One notable limitation is that GINA provides no
protection against genetic discrimination by insurers selling policies for life, disability, or
long-term care insurance, or discrimination by creditors based on genetic information.
Hudson et al., supra note 224, at 2662. “This [was] not the result of oversight: a strategic
decision was made early on to recognize the very distinct markets, social purposes, risks of
adverse selection, and bodies of relevant law governing these types of insurance.” Id. at
2663. As of 2017, forty-eight states and the District of Columbia have instituted their own
laws prohibiting genetic discrimination by health insurance providers, and thirty-five states
and the District of Columbia have prohibitions against genetic discrimination in
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rights developed in stages,” GINA represents “only a first step”
toward protecting the American people from discrimination based on
genetic information.257 The law is imperfect and does not provide as
much protection as some organizations and families may have
hoped,258 and even with GINA in place the risk of a “genetic
underclass” persists.259 Gaps in legal protections make equitable
access to gene-editing treatments all the more important, as GINA
will not protect individuals with SCD against discrimination in the
workplace or in obtaining insurance. This, and the tenuous status of
ACA preexisting condition protections, leaves the SCD community
with a pressing need for not only a cure but a cure that is affordable.
Being blocked from workplace participation and affordable health
care (which often is obtained through one’s workplace), the
community experiences a heightened vulnerability and need for
solutions.
Perhaps the most striking of GINA’s limitations is that once an
individual’s genetic condition manifests or is diagnosed, that person
no longer qualifies for GINA protections.260 So, for example, in the

employment. Genetic Discrimination and Other Laws, NIH: NAT’L HUM. GENOME RES.
INST. (Apr. 17, 2017), https://www.genome.gov/27568503/genetic-discrimination-and-otherlaws [https://perma.cc/8VTT-TVG8]. Mississippi and Washington are the only two states
that have not passed laws prohibiting genetic discrimination in health insurance. Id. Some
states have bolstered GINA protections by including prohibitions against genetic
discrimination in “other insurances,” including those for life, disability, and long-term care
policies. Id. As of 2017, seventeen states have additional laws restricting the use of genetic
information in determining coverage for life insurance, seventeen states for disability
insurance, and eight states for long-term care insurance. Id. Three years after GINA’s
passage, the state of California passed the California Genetic Information
Nondiscrimination Act (“CalGINA”), which expands GINA’s protections by prohibiting
genetic discrimination in emergency medical services, housing, mortgage lending,
education, state-funded services, and public accommodation and also lowers the employee
amount to five (from the more permissive fifteen-employee threshold under GINA). CAL.
GOV’T CODE §§ 1135, 12920 (West 2018); see also Slaughter, supra note 112, at 63. In
2016, Maryland imposed restrictions on life insurance companies, prohibiting unfair
discrimination between individuals of the same class and equal life expectancy, and made
specific mention of SCT. MD. CODE ANN., INS. § 27-208 (Westlaw through legis. effective
Apr. 30, 2019, from the 2019 Reg. Sess.).
257. Slaughter, supra note 112, at 59.
258. Hudson et al., supra note 224, at 2662. For example, it is argued that if diagnosed
genetic illnesses had been included within GINA’s protections, this would have caused
economic disruption in the individual health insurance market which, at that time,
underwrote on the basis of diagnosed diseases. Id. at 2662–63. Further, from an ethics
standpoint, it would have been “fundamentally unjust to treat people with genetic diseases
differently from those whose diseases are nongenetic or have unknown causes.” Id. at
2663.
259. Ajunwa, supra note 213, at 90.
260. See supra note 249 and accompanying text.
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context of the SCD and SCT community, an infant testing positive for
SCT is a carrier of a genetic variant but does not have the disease and,
thus, is protected by GINA.261 By contrast, an infant who tests
positive at birth for SCD seems to be stripped of GINA’s protections
because he or she has a diagnosed genetic condition. As Keith Wailoo
states, “[T]he experience of the illness varies greatly from one person
to the next. In some, pain and infection are overwhelming and
recurrent, and in others such symptoms are barely discernible.”262 But
this fact is irrelevant under GINA, which appears to draw bright,
unyielding lines.
Currently, individuals facing discrimination based on SCD must
rely on clever combinations of federal and state laws, other than
GINA, to assert their rights.263 Legislation specifically extending
protections to those with genetic diseases—manifested and/or
diagnosed—is needed to meaningfully advance the cause of members
of the SCD community who suffer discrimination in the workplace
and in obtaining insurance, especially if ACA protections are
eliminated. If federal legislators are unable or unwilling to implement
changes, state legislators and governors can play a substantial role in
bringing forth change. While GINA provides a baseline of protection
at the national level, some states have crafted even broader
safeguards to supplement those provided under GINA, although
these state laws vary widely in scope, applicability, and degree of
protection.264 GINA sets a floor of minimum protection against
genetic discrimination; state laws with stricter protections are not
preempted.265
The law’s response when CRISPR technology successfully cures
genetic disease will be noteworthy. Unless clarified through new
legislation or regulations, the courts will need to address reconciling
GINA’s approach to the manifested genetic disease with an outcome
GINA did not anticipate: the cured genetic disease. What type of

261. See supra note 249 and accompanying text. As we learn more about sickle cell
carrier status and other diseases with a recessive pattern of inheritance, in rare
circumstances, having one allele may have clinical complications. Should this be
considered “manifested disease” for purposes of GINA? We assert carrier status is not
clinical manifestation of a genetic disease.
262. WAILOO, supra note 85, at 9.
263. For case law describing the legacy of discrimination and recognized patients’
rights, see supra Part III.
264. Genetic Discrimination and Other Laws, supra note 256. Some of these laws
predated GINA, and some were enacted subsequent to GINA. Id.
265. Id.; see also Hudson et al., supra note 224, at 2662. For a discussion of more
extensive state law protections, see text accompanying supra note 256.
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proof will be necessary to restore an individual’s protection under
GINA? These are among the questions the law will need to
contemplate. But first, there are more salient questions regarding how
best to achieve and ensure equitable access to SCD cures. For the
SCD community, which historically has experienced health inequities,
this is a critical concern.
VI. EQUITY AND GENOME EDITING
Thus far, the Article has highlighted how gene editing is a source
of hope for the SCD community, explored the community’s
skepticism and fear in embracing that hope and examined reasons
why the community might be distrustful of government agencies,
researchers, and some health-care providers. The Article spotlighted
instances of this community’s experienced history of discrimination
and described the inadequacy of current legal protections. This part
highlights additional concerns surrounding equitable access to gene
editing in the context of SCD. It concludes by summarizing why
equity concerns should be paramount in treatment and research
efforts surrounding gene editing in SCD and then offers initial
thoughts on how such equity concerns can remain central to future
work.
A. Disparity Diseases and Civil Rights
SCD adversely impacts U.S. populations that already experience
significant health disparities.266 Congress defined health disparities as
“a significant disparity in the overall rate of disease incidence,
prevalence, morbidity, mortality, or survival rates in the population as
compared to the health status of the general population” in the
Minority Health and Health Disparities Research and Education Act
of 2000.267 Healthy People 2020 defines a health disparity as
a particular type of health difference that is closely linked with
social or economic disadvantage. Health disparities adversely
affect groups of people who have systematically experienced
greater social or economic obstacles to health based on their
racial or ethnic group, religion, socioeconomic status, gender,
mental health, cognitive, sensory, or physical disability, sexual

266. Michele Goodwin, Revisiting Death: Implicit Bias and the Case of Jahi McMath,
HASTINGS CTR. REP., Nov.–Dec. 2018, S77, S78–S79.
267. 42 U.S.C. § 285t(d)(1) (2012).
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orientation, geographic location, or other characteristics
historically linked to discrimination or exclusion.268
As stated earlier, African ancestral populations have the highest rates
of SCD in the United States and, overall, also experience greater
health inequities and health disparities.269 Although SCD is far more
prevalent than other rare genetic diseases, historically, less funding,
research, and overall attention has been allocated for SCD
treatment.270
Addressing health disparities is a civil rights issue. “Civil rights
laws and their enforcement are social determinants of health because
they affect other social determinants of health . . . such as education,
housing, transportation, employment, and the system of justice
. . . .”271 As such, civil rights laws “causally affect the societal
distribution of resources that in turn affect disease, injury, and
health.”272 Health equity is the principle to address disparities in
health, striving for the highest possible standard of health for all.273
The disparities that exist in the treatment of SCD must be
contextualized in the development of the human genome-editing
technology aimed at the disease’s treatment and prevention. If
researchers, biotechnology firms, and policymakers are not mindful of
this context, we are concerned that this disease, burdened with the
legacy of neglect, will not benefit equally in genetic editing.

268. U.S. DEP’T OF HEALTH & HUM. SERVS., THE SECRETARY’S ADVISORY
COMMITTEE ON NATIONAL HEALTH PROMOTION AND DISEASE PREVENTION
OBJECTIVES FOR 2020, at 28 (2008), https://healthypeople.gov/sites/default/files/
PhaseI_0.pdf [https://perma.cc/PJN2-LTP4].
269. CDC Health Disparities & Inequalities Report, CENTERS FOR DISEASE CONTROL
& PREVENTION, https://www.cdc.gov/minorityhealth/CHDIReport.html [https://perma.cc/
J7RX-JY7A].
270. Scott, supra note 98, at 731.
271. R.A. Hahn, B.I. Truman & D.R. Williams, Civil Rights as Determinants of Public
Health and Racial and Ethnic Health Equality: Health Care, Education, Employment, and
Housing in the United States, 4 SSM POPULATION HEALTH 17, 17–18 (2018).
272. Id.
273. Paula Braveman, What Are Health Disparities and Health Equity? We Need to Be
Clear, 129 PUB. HEALTH REP. 5, 6, 7 (2014) (“Health equity and health disparities are
intertwined. Health equity means social justice in health (i.e., no one is denied the
possibility to be healthy for belonging to a group that has historically been
economically/socially disadvantaged). Health disparities are the metric we use to measure
progress toward achieving health equity. A reduction in health disparities (in absolute and
relative terms) is evidence that we are moving toward greater health equity.”).
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Ensuring Equitable Access Globally and the Legal and Economic
Obstacles

Equity and fairness in access to new curative genetic therapies is
not limited to the United States and Europe. It is important to note
the extensive burden of SCD outside of high-income countries.
Estimates of infants born with sickle cell anemia annually range from
300,000 to 400,000.274 The vast majority of these births occur in three
countries: Nigeria, the Democratic Republic of the Congo, and
India.275 Approximately 1000 babies are born with SCD in Africa
every day and more than half will die before their fifth birthday.276
Piel and colleagues report that the global burden is increasing and
highlight the need for low- and middle-income countries to develop
national policies for newborn screening, public health planning, and
treatment.277 Researchers contemplating the potential of human
genome editing as a genetic curative strategy for SCD must also
question the impact for low- and middle-income countries
experiencing the greatest burden of this disease. Low- and middleincome countries are even less equipped to conduct (ex vivo) human
genome editing, especially when considering the unsustainable cost
anticipated in high-income countries.278
However, leaders in global health and development are looking
to use CRISPR and other genome-editing technologies to help
humanity overcome some of its biggest and most persistent
challenges.279 For example, the director of the NIH, Francis Collins,
274. Piel et al., Sickle Cell Disease, supra note 25, at 1561.
275. Id.
276. World
Sickle
Cell
Day,
SICKLE
CELL
DISEASE
COALITION,
http://www.scdcoalition.org/priorities/global.html [https://perma.cc/S9QP-YGGJ].
277. Piel et al., Global Burden, supra note 30, at 9.
278. “Currently, most gene therapy trials for [SCD] are ex vivo. However, ex vivo gene
therapy is a complicated, multi-step process that takes weeks and requires
hospitalization.” Alice Dickow, The Gates Foundation Backs Gene Editing Research to
Treat a
Devastating
Disease,
INSIDE PHILANTHROPY
(Mar.
2, 2019),
https://www.insidephilanthropy.com/home/2019/3/3/the-gates-foundation-backs-gene-editingresearch-to-treat-a-devastating-disease [https://perma.cc/RU9M-Q7H5]. Researchers are
developing methods that allow in vivo gene-therapy applications for SCD in areas of the
world where health-care systems are less developed than in the United States and Europe.
Id.
279. See, e.g., Bill Gates, Gene Editing for Good: How CRISPR Could Transform
Global Development, FOREIGN AFF. (Apr. 10, 2018), https://www.foreignaffairs.com/
articles/2018-04-10/gene-editing-good [https://perma.cc/FSQ5-BKJC] (“The technology is
making it much easier for scientists to discover better diagnostics, treatments, and other
tools to fight diseases that still kill and disable millions of people every year, primarily the
poor. It is also accelerating research that could help end extreme poverty by enabling
millions of farmers in the developing world to grow crops and raise livestock that are more
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discussed how genome editing may accelerate a cure for SCD, noting
that
[t]he complicated, high-tech procedures . . . may not be practical
for a very long time in places like sub-Saharan Africa. That’s
one reason why NIH recently launched a new effort to speed
the development of safe, effective genome-editing approaches
that could be delivered directly into a patient’s body (in vivo),
perhaps by infusion of the CRISPR gene editing apparatus.280
Moreover, at the end of 2018, the Bill and Melinda Gates Foundation
awarded a $1.5 million grant to Boston Children’s Hospital to
research and develop gene-therapy treatment for SCD with the longterm goal of making the treatment available to patients in developing
countries.281
Exploring the legal, policy, and social implications of genome
editing includes grappling with this question of whether low- and
middle-income countries and their citizens will benefit from this new
technology. If the goal is truly to benefit those suffering from SCD,
the scientific agenda must develop and implement an international
framework for somatic human genome editing that is accessible to the
millions of sub-Saharan African and Indian people with this disease.
However, patent disputes and the projected exorbitant costs of
treatment may hinder progress with respect to developing and
perfecting CRISPR biotechnology.
1. Legal Disputes Could Slow Clinical Trials and Treatment
While there is optimism about the scientific community’s
commitment to finding a cure, patent litigation between leaders282 in
productive, more nutritious, and hardier. New technologies are often met with skepticism.
But if the world is to continue the remarkable progress of the past few decades, it is vital
that scientists, subject to safety and ethics guidelines, be encouraged to continue taking
advantage of such promising tools as CRISPR.”).
280. Collins, supra note 62.
281. David A. Williams, Boston Children’s Hospital Receives Grant for Sickle Cell
Disease Research, HEALIO (Dec. 30, 2018), https://www.healio.com/hematology-oncology/
hematology/news/online/%7B9ba22126-f234-457d-bfd7-23fef382e43c%7D/boston-childrenshospital-receives-grant-for-sickle-cell-disease-research [https://perma.cc/8P9K-29DT] (“While
gene therapies are currently confined to a few research hospitals in the U.S. and other
developed countries, our long-term goal is to make this treatment available to patients in
developing countries—and we have already begun to think about how to translate this
specialized, potentially curative therapy.”).
282. The University of California, Berkeley (“UC Berkeley”), with the University of
Vienna and Emmanuelle Charpentier, and the Broad Institute, with MIT and Harvard,
are parties involved in the litigation over patent rights to the CRISPR-Cas9 gene-editing
technology. See Univ. of Cal. v. Broad Inst. Inc., 903 F.3d 1286, 1286 (Fed. Cir. 2018).
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the CRISPR-Cas9 field has complicated matters in the United
States283 and in Europe.284 Final outcomes of these matters are
critically important because they determine who holds which rights,
who may decide on and implement future research with the
biotechnology, and who may grant licenses for its use. Most
importantly, patent litigation could potentially stall development of
curative genetic therapies.
However, forward momentum is evident in clinical trials. For
example, in April 2018, sponsor CRISPR Therapeutics and
collaborator Vertex submitted an Investigational New Drug (“IND”)
Application to the FDA for the treatment of adults with SCD using
CTX001 CRISPR technology.285 In late May 2018, the FDA placed a
283. See id. On September 10, 2018, the Federal Circuit upheld the U.S. Patent &
Trademark Patent Trial and Appeal Board (“PTAB”) determination in favor of the Broad
Institute. Id. at 1296. The Federal Circuit held that though Doudna (of UC Berkeley) and
Charpentier (of the University of Vienna) were first to publish their CRISPR-Cas9
findings, Doudna & Charpentier, supra note 22, demonstrating that the isolated elements
of the CRISPR-Cas9 system could be used in vitro in a noncellular experimental
environment, the Broad researchers’ February 2013 article described use of CRISPR-Cas9
in a human cell line. Id. at 1289. A distinction made by the PTAB is that CRISPR-Cas
systems occur naturally in prokaryotes such as bacteria but have not been found to
naturally exist in eukaryotes, such as plants and animals. Id. The court found that
substantial evidence supported the PTAB’s determination that, given the differences in
eukaryotic cells and prokaryotic systems, a person of ordinary skill in the art would not
have had a reasonable expectation of success in applying the CRISPR-Cas9 system in
eukaryotic cells. Id. at 1290, 1296. The court agreed with the PTAB that UC Berkeley’s
claims to the use of CRISPR-Cas9 did not “render obvious” Broad’s claims to its use in
eukaryotes. Id. The Federal Circuit noted that this position could be supported in the
record. Id. at 1294. “The prior art contained a number of techniques that had been used
for adapting prokaryotic systems for use in eukaryotic cells, obstacles adopting other
prokaryotic systems had been overcome, and [the UC Berkeley team] suggested using
those techniques to implement CRISPR-Cas9 in eukaryotes.” Id. The court, however,
went on to note that its function was appellate in nature and that it was not at liberty to
reweigh the evidence. Id. “It is not our role to ask whether substantial evidence supports
fact-findings not made by the Board, but instead whether such evidence supports the
findings that were in fact made.” Id. For an excellent update on the Broad Institute
litigation, see Sharon Begley, University of California to be Granted Long-Sought CRISPR
Patent, Possibly Reviving Dispute with the Broad Institute, STAT: BIOTECH (Feb. 8, 2019),
https://www.statnews.com/2019/02/08/the-university-of-california-gets-its-key-crispr-patent
[https://perma.cc/4JHD-XMBJ].
284. See EP2800811 – Methods and Compositions for RNA-Directed Target DNA
Modification and for RNA-Directed Modulation of Transcription, EUR. PAT. REG. (Dec.
26, 2018), https://register.epo.org/application?number=EP13793997&lng=en&tab=main
[https://perma.cc/8977-6BU4]. The same plaintiffs that were unsuccessful in the Broad
Institute litigation prevailed in their European patent challenge against the same
defendants before the European Patent Office and were granted a broad European patent
for CRISPR-Cas9. Id.; see also Broad Inst., 903 F.3d at 1286.
285. CRISPR Therapeutics and Vertex Provide Update on FDA Review of
Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease,
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hold on the proposed clinical trial, but that hold was lifted by October
2018.286 The FDA had certain questions that it required the sponsors
to resolve before approval of the Phase I-II trial but has now accepted
the IND Application and will allow the early-phase clinical trial to
proceed.287 The sponsors also have obtained approvals of clinical trial
applications in multiple countries for both β-thalassemia and SCD.288
At the December 2018 American Society of Hematology Annual
Meeting, a team of scientists reported that the CRISPR technology
data shows that the “BCL11A enhancer editing approach[] . . . is a
practicable therapeutic strategy to produce durable HbF induction in
SCD and β-thalassemia.”289 Genome editing to increase HbF has the
potential to alleviate transfusion requirements for β-thalassemia
patients and painful and debilitating sickle crises for sickle cell
patients.290
2. Costs and Who Will Pay?
Affordability is a key consideration when making decisions
about advancing genetic science. Particularly, is it worth it to invest in
converting the science into therapies for which we will have to pay
significant sums of money?291 This is a major concern of the SCD
community. It is also a worry of legislators in states concerned about

CRISPR THERAPEUTICS (May 30, 2018), https://globenewswire.com/news-release/2018/05/
30/1514301/0/en/CRISPR-Therapeutics-and-Vertex-Provide-Update-on-FDA-Reviewof-Investigational-New-Drug-Application-for-CTX001-for-the-Treatment-of-Sickle-CellDisease.html [https://perma.cc/6FEU-SVY8] [hereinafter Update on FDA Review].
286. Id.; CRISPR Therapeutics and Vertex Announce FDA Has Lifted the Clinical Hold
on the Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell
Disease, CRISPR THERAPEUTICS (Oct. 10, 2018), https://globenewswire.com/newsrelease/2018/10/10/1619581/0/en/CRISPR-Therapeutics-and-Vertex-Announce-FDA-HasLifted-the-Clinical-Hold-on-the-Investigational-New-Drug-Application-for-CTX001-for-theTreatment-of-Sickle-Cell-Disease.html
[https://perma.cc/SD4C-ETAX]
[hereinafter
CRISPR Therapeutics]; Alex Keown, FDA Lifts Clinical Hold; Green-Lights Vertex and
CRISPR’s Sickle Cell Gene Therapy Trial, BIOSPACE (Oct. 11, 2018),
https://www.biospace.com/article/fda-lifts-clinical-hold-green-lights-vertex-and-crispr-ssickle-cell-gene-therapy-trial/ [https://perma.cc/Z2A3-TSP9].
287. CRISPR Therapeutics, supra note 286.
288. See Pipeline: Tackling a Range of Diseases with Different Approaches, CRISPR
THERAPEUTICS, http://www.crisprtx.com/programs/pipeline [https://perma.cc/2PVE-JCVY].
289. Am. Soc’y of Hematology, 3482 Highly Efficient Therapeutic Gene Editing of
BCL11A Enhancer in Human Hematopoietic Stem Cells from ß-Hemoglobinopathy
Patients for Fetal Hemoglobin Induction, ASH HOME (Dec. 2, 2018), https://ash.confex.com/
ash/2018/webprogram/Paper119365.html [https://perma.cc/SF3G-5TNX].
290. Update on FDA Review, supra note 285.
291. Erika Check Hayden, Gene Therapies Pose Million-Dollar Conundrum, 534
NATURE 305, 305 (2016).
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an inability to cover costs of available treatments.292 While new
treatments for SCD and other serious diseases are great news for
patients, even called “a Renaissance for treatments of longuntreatable illnesses,” states may have some very difficult decisions to
make.293 One cost-covering solution on the rise is a deal brokered
between drug companies and insurers, known as “pay for
performance,” whereby insurer payments are tied to a medicine’s
actual performance; if patients fail to reach some pre-agreed-upon
therapeutic response or the insurer ends up paying more than it has
budgeted, the pharmaceuticals manufacturer refunds money to the
insurer.294 Such deals are estimated to be in play in fourteen countries,
mostly in the United States and Europe but also in middle-income
countries, including Brazil.295
Some scientists are exuberant about the potential for CRISPR in
treating classic genetic diseases like SCD, believing that CRISPR not
only will be transformative but also will make gene editing “cheap,
easy and accessible, and therefore more common.”296 According to
bioethicist Mildred Cho, however, even if CRISPR proves successful
in clinical trials, the actual treatment will be cost prohibitive for many
patients.297 Emphasizing the significant differences between
undergoing gene-therapy treatment and taking a pill from a
pharmacy, Cho states: “It’s more like getting an organ transplant. It’s
a very complex procedure. Cancer immunotherapy already costs in
the hundreds of thousands of dollars per year. There’s no way that
gene-edited treatments are going to be any less expensive.”298
With any CRISPR technology approved for use in treating SCD,
there will be no existing approved drugs that work similarly, thus
there may be little competition or incentive for companies to keep
prices affordable.299 This is a major reason why there should be some
type of agreement, understanding, or bargain between the SCD
community and pharmaceutical companies that study CRISPR
technology in clinical trials using volunteers from the sickle cell
292. Michael Booth, Effective But Very Expensive Drugs Are Forcing State Medicaid
Directors to Make Some Tough Decisions, NAT’L CONF. ST. LEGISLATURES (Feb. 1,
2017),
http://www.ncsl.org/bookstore/state-legislatures-magazine/effective-but-expensivedrugs-are-beyond-the-reach-of-many.aspx [https://perma.cc/BNG3-E7KV].
293. Id.
294. Hayden, supra note 291, at 306.
295. Id. Data gathering and sharing centers are part of these arrangements. See id.
296. Shwartz, supra note 11, at 27.
297. Id. at 26.
298. Id.
299. Hayden, supra note 291, at 306.
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community. These patients, and those in their community, must reap
lasting benefits from any positive discoveries in research that they
help to move forward.
One option that may foster equitable access can be seen in
public-private partnerships. Through public-private partnerships,
philanthropic foundations commit resources to diseases or causes and
act as facilitators in brokering agreements and negotiating promises
of affordability and access.300 Recently, the Duke Charitable
Foundation has funded the Critical Path Institute (“C-Path”) for
development of advances in therapies for SCD.301 C-Path has a publicprivate partnership with the FDA and an established record of
building consortia to speed development of novel medical therapies
for patients suffering from various diseases and conditions.302 The
Duke Charitable Foundation lists sickle cell patient advocacy groups
as stakeholders that will be part of the conversation.303 Hopefully,
affordability and access—both initially and long-term—will be central
to the discussion.
Another, more mature C-Path endeavor, in collaboration with
The Bill & Melinda Gates Foundation, is an initiative to develop
effective treatments for Tuberculosis.304 That program specifically
addresses concerns about the “dire need for faster-acting drugs to
treat TB in all its forms that are effective, affordable, and
accessible.”305 Other disease-specific initiatives are the ACT Initiative
of the National Hemophilia Foundation306 and the Kidney Innovation

300. See, e.g., Press Release, Critical Path Inst., Doris Duke Charitable Foundation
Awards Grant to Critical Path Institute to Advance Therapies for Sickle Cell Disease
(Sept. 6, 2018), https://c-path.org/doris-duke-charitable-foundation-awards-grant-tocritical-path-institute-to-advance-therapies-for-sickle-cell-disease/ [https://perma.cc/8BN3E2KH].
301. Id.
302. Id.
303. Id.
304. Critical Path to TB Drug Regimens, CRITICAL PATH INST., https://c-path.org/
programs/cptr/ [https://perma.cc/LUT4-SRYG].
305. Id.
306. The National Hemophilia Foundation implemented the ACT initiative with
numerous partners from the biopharmaceuticals industry “to meet the imperative need to
build [the] national capacity to maintain, and achieve where lacking, access to care for
people with bleeding disorders.” The ACT Initiative, NAT’L HEMOPHILIA FOUND.,
https://www.hemophilia.org/About-Us/Access-to-Care-Today-Achieving-Cures-Tomorrow
[https://perma.cc/HDK9-N8ZH]. The National Hemophilia Foundation defines access as
follows: “[a]dherence to state-of-the-art standards of care, [a]ccess to hemophilia
treatment centers (HTCs), [a]ccess to treatment products appropriate for the individual,
and [a]dequate reimbursement for these life-saving therapies.” Id.
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Accelerator (“KidneyX”).307 These more established programs and
their emphasis on affordability and access can serve as examples as
the newer SCD C-Path moves forward.
CONCLUSION
The promise of genome editing to address the burden of SCD is
profound. The possibility that it will cause harm and will not
equitably benefit those living with SCD in high-income countries,
such as the United States, is real. With an eye toward ensuring
equitable access, scientists, ethicists, economists, lawyers, and
policymakers must develop new approaches to implement this new
and expensive treatment in a population recognized to have been
underserved.
The stakes are high. The challenge is to foresee obstacles to
access and affordability now, as Phase I clinical trials are being
conducted, so that the SCD community is not left with a solution and
no means of using it to solve this life-and-death problem. Currently,
in low-income countries with the highest burden of SCD, the
potential to benefit from genetic curative therapies and genome
editing is unrealistic when those countries do not even have resources
to implement newborn screening and preventive care.308 If the United
States and other scientifically advanced countries are able to get the
science right, we can and must share our knowledge and resources
with low-income countries carrying the highest burdens of the
disease.
The National Academies of Sciences 2017 Report identified
seven principles that should undergird the oversight systems, research
on, and eventual clinical uses of human genome editing: (1)
promoting well-being, (2) transparency, (3) due care, (4) responsible
science, (5) respect for persons, (6) fairness, and (7) transnational
307. The Kidney Innovation Accelerator (KidneyX) is a public-private partnership
designed to accelerate innovation in prevention, diagnosis, and treatment of kidney
disease. HHS Announces Kidney Innovation Accelerator at ASN Kidney Week 2017, ASN
(Jan. 9, 2018), https://www.asn-online.org/news/item.aspx?ID=144 [https://perma.cc/
RBX6-8TYY]. “The Accelerator will establish a public-private innovation fund capable of
seeding and accelerating not just incremental improvements in treating kidney disease, but
will foster real breakthroughs in dialysis and other treatments for kidney disease.” Id. In
order to ensure that the path to commercialization is “straight and clear,” the Accelerator
will bring together key components of HHS, notably the FDA, CMS, and the NIH. Id.
308. Lewis Hsu et al., White Paper: Pathways to Progress in Newborn Screening for
Sickle Cell Disease in Sub-Saharan Africa, 6 J. TROPICAL DISEASES, no. 1000260, July 10,
2018, at 1, 5; Bertin Tshimanga Kadima et al., High Rate of Sickle Cell Anaemia in SubSaharan Africa Underlines the Need to Screen All Children with Severe Anaemia for the
Disease, 104 ACTA PAEDIATRICA 1269, 1272 (2015).
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cooperation.309 Each principle is essential to implementation of
genome editing for SCD. The first five reflect requirements or
aspirations clearly articulated in existing U.S. laws and policies
relating to human subjects research. The last two, fairness and
transnational cooperation, more easily have been bypassed in the race
to develop new treatments for ailments in high-income countries.
The future will be bright for those who carry the burden of SCD
as an everyday life experience . . . provided that we prioritize the
development of strategies to equitably integrate these new curative
genetic therapies. With commitment, cooperation, and careful
planning, we could forever reduce the burden of this disease.

309. NAT’L ACADS. SCI., ENG’G, & MED., supra note 5, at 11–12.
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